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Abstract 
Abstract 
Osteoporosis is as old as the origin of human civiUzation yet complete understanding 
about it remains to be achieved till date. Osteoporosis and associated fractures 
constitute a major public health issue together representing an important cause of 
mortality and morbidity with armual incidence of fracture rates exceeding the 
combined incidence of breast cancer, stroke and heart attacks in postmenopausal 
women (PMW). Emergence of osteoporosis as a global bone health concern is 
reflected in the occurrence of 1.6 million hip fractures annually worldwide and the 
number projected to go up four times by 2050. Though osteoporosis affects both men 
and women, the later are more susceptible targets of this crippling disorder of bone. 
Osteoporosis has been recognized as that infection, inflammation, and autounmime 
disorders are associated with systemic and local bone loss. However, it is only recent 
that T lymphocytes and their product have been recognized as key regulators of bone 
cell formation, lifespan and activity. Of many proinflammatory cytokines activated in 
osteoporosis, TNF-a is probably the dominant cytokine, which promotes 
osteoclastogenesis by augmenting the production of RANKL, the non-redundant 
cytokine responsible for osteoclast development. This ability of TNF-a is due to 
synergistic interactions at the level of NF-KB and activator protein-1 (AP-1) signaling. 
Furthermore, TNF stimulates osteoclast (OC) activity and inhibits osteoblastogenesis 
thus fiirther driving an imbalance between bone formation and bone resorption. With 
ever increasing number of elderly people in the population, improved survival and an 
increase in the age-specific fracture rates, there is an immediate need to develop new 
cost-effective therapeutic strategies against osteoporosis. Thus, in the present study 
allicin from garlic and EGCG from green tea were employed in order to investigate 
the above. 
Allicin, from garlic is the major biologically active thiosulfinate compound of freshly 
crushed garlic. It has been reported to possess potent antibacterial properties besides 
showing broad range antimicrobial and antifimgal activities. Besides, allicin has 
radical scavenging properties in activated granulocytes and may also inhibit iNOS 
expression in activated macrophages. EGCG-a green tea polyphenol, is one of the 
most versatile medicinal plants having a wide spectrum of biological activity. Both 
allicin and EGCG have been reported to have multiple properties some of which 
Page i 
Abstract 
include anti-inflammatory, immunostimulatory, anti-malarial, anti-mycobacterial, 
antipyretic, anticarcinogenic, anti-oxidant and analgesic activities. 
In view of reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
playing an important role in both estrogen related and unrelated osteoporosis, thus, 
greater emphasis now being laid on development of compounds from natural sources 
having antioxidant and anti-inflammatory properties in combating osteoporosis. 
Earlier work in our laboratory has proved the antioxidant and anti-inflammatory 
effects of allicin from garlic in other diseases. Thus, we studied the incorporation of 
such compounds like allicin from garlic, and EGCG- a green tea polyphenol as well 
as a natural antioxidant in the freatment for bone loss. 
The initial phase of the present study undertook a detailed characterization of sera and 
monocytes of osteoporosis patients to assess the activity of predominant antioxidant 
enzyme, GPx and to measure the intramonocyte (GSH) levels. Glutathione (GSH) 
directly reacts with ROS and glutathione peroxidase (GPx) catalyses the removal of 
hydrogen peroxide. ELISA results showed almost less than half the activity of 
enzyme both in sera and monocytes of osteoporosis patients as compared to healthy 
individuals. Decrease in GPx activity therefore, indicates impairment of hydrogen 
peroxide-neutralizing mechanism. A similar suppression in intramonocyte GSH levels 
was observed in these patients indicative of weak antioxidant power. The presence of 
elevated free radicals in osteoporosis patients was also substantiated by MDA 
determination. 
Next, the levels of malondialdehyde (MDA), a by-product of lipid peroxidation were 
observed to be appreciably high both in sera and monocyte cultures of osteoporosis 
patients further pointing to the increased oxidant stress in such patients. Subsequent 
increase in hydrogen peroxide levels due to depressed GSH levels and GPx activity in 
osteoporosis patients might have induced the peroxidation of polyunsaturated fatty 
acids, thereby leading to the formation of high MDA levels. Moreover, due to high 
reactivity of MDA towards amino groups may also lead to deactivation of enzymes. 
Allicin and EGCG dose-dependently down-regulated the excess levels of MDA in 
monocyte cultures of osteoporosis patients. 
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Multiple evidences suggest that estrogen prevents bone loss by blocking the 
production of proinflammatory cytokines by bone marrow stromal and bone cells. 
Cytokines regulated by estrogen are IL-1, IL-6 and TNF a. In our study also, probe by 
ELISA showed an appreciable secretion of TNF-a and IL-ip in the sera and 
monocytes of osteoporosis patients. Infact, IL-1 is a potent stimulator of bone 
resorption together with TNF, and both are well-recognized inhibitors of bone 
formation. IL-1 and TNF are also powerful inducers of other cytokines such as IL-6, 
M-CSF and GM-CSF, which potentiate the effect of IL-1 on osteoclastogenesis. 
Next, an attempt was also made to characterize monocytes from osteoporosis patients 
with respect to TNF-a and osteoprotegrin (OPG). Monocytes from these patients were 
subjected to TNF-a and OPG mRNA evaluation by real-time RT-PCR revealing 
appreciably high basal levels of both mRNA expressions. 
The role of OPG in the pathogenesis of osteoporosis has not been clear since OPG 
levels are not consistently altered. In humans, OPG levels increasing with age are 
understood as a homeostatic response to limit the bone loss that occurs with an 
increase in other bone resorbing factors. Thus, in the present study, we attempted to 
probe the expression level of OPG and RANKL together with TNF a and their 
regulation by natural antioxidants like allicin from garlic and EGCG from green tea in 
osteoporosis. 
In order to probe the above, in the present study, a real-time RT-PCR was carried out, 
where the data exhibited that both allicin and EGCG down-regulated the expression of 
TNF-a and OPG mRNA in PBMC's of osteoporosis patients in a dose-dependent 
manner. Concentrations of 250 and 500 ng/ml of allicin and that of 15 jiig/ml and 
20 ng/ml of EGCG respectively were found to suppress the appreciably high basal 
levels of TNF and OPG mRNA's by an appreciable degree. It is to be pointed out that 
previous reports indicated higher doses of allicin were toxic to human cells. Similarly, 
previous reports show that concentrations of EGCG above 23 pg/ml induced 
apoptosis in mononuclear cells. However, our laboratory has shown lower doses of 
allicin (0-500 ng/ml) as well as EGCG (0-20 ^g/ml) to be non-toxic and proved to be 
potent anti-inflammatory agent in other disease conditions such as tuberculosis. From 
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our data, it is evident that whereas low concentrations of alUcin and EGCG used in 
this study appreciably down-regulate the mRNA expression of TNF a and OPG, at the 
same time show no significant effect on the expression of human housekeeping gene 
Rl 8. Thus, low dose of allicin and EGCG used in the study was non-toxic. 
Although OPG is produced in many tissues, bone derived OPG may be released into 
circulation, thereby reflecting the situation locally in bone. Our results showing 
increased OPG mRNA expression in the osteoporosis patient PBMC's therefore may 
indicate a compensatory response to increased osteoclastic bone resorption and the 
resultant bone loss caused by estrogen deficiency; this considering the fact that OPG 
has bone sparing activity. The expression of OPG mRNA correlated positively with 
that of TNF a mRNA expression. Therefore, OPG, a soluble member of TNFR super 
family of proteins plays an important role in the negative regulation of osteoclastic 
bone resorption. 
Next, as RANKL is necessary for osteoclast differentiation, thus the levels of RANKL 
in monocyte cultures of osteoporosis patients in comparison to healthy controls was 
also probed. Our results showed that in comparison to healthy controls, the patient's 
cultures exhibited around 9-fold augmented levels of RANKL. Thereafter, dose 
response effects of allicin and EGCG showed interesting results. In case of 
osteoporosis patients, sRANKL secretion dose-dependently decreased fi"om 
30.68 pg/ml at through 25.36, 18.12, 9.56 and 4.01 pg/ml with 50, \Q0, 250 and 500 
ng/ml allicin respectively (P<0.001). Computation of the data revealed that allicin 
down regulated / suppressed the secretion of sRANKL by around 17.34%, 40.93%, 
68.83% and 86.92% with 50, 100, 250 and 500 ng/ml allicin respectively. The IC50 
was computed out to be in between 100-125 ng/ml. Similarly, in case of osteoporosis 
patients, sRANKL secretion was found to dose-dependently decrease from 
32.65 pg/ml at through 27.81, 22.45, 17.29, 13.07 and 9.44 pg/ml with 2, 5, 10, 15 
and 20 ng/ml EGCG respectively. Computational analysis of the data revealed that 
EGCG down regulated / suppressed the secretion of sRANKL by around 14.82%, 
31.24%, 47.04%, 59.96% and 71.08% with 2, 5, 10, 15 and 20 ng/ml EGCG 
respectively. The IC50 was computed out to be in between 7.5-10 ng/ml of EGCG. 
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TRAP assay data revealed healthy control monocyte cultures did not show any 
multinucleated cells/osteoclasts, whereas those from osteoporosis patient exhibited 
appreciable number of multinucleated cells/osteoclasts. Interestingly, monocyte 
cultures of 5 days for osteoporosis patient that were co-cultured with 2 ng/ml of 
TNF-alpha exhibited an enhanced number of multinucleated cells/osteoclasts, when 
compared to cultures devoid of any TNF-alpha. Furthermore, in monocyte cultures of 
osteoporosis patient, when co-cultured with 500 ng/ml of allicin and 20 |ig/ml of 
EGCG respectively for 5 days, the TRAP assay data showed that both 500 ng/ml 
allicin as well as 20 )ig/ml EGCG, inhibited / suppressed / down-regulated the 
formation of multinucleated cells/osteoclasts. The suppression was clearly more m 
cultures receiving allicin in comparison to EGCG. 
Next, secretion of cytokine IL-ip and generation of ROS, as reflected by suppressed 
GPx activity and GSH levels in osteoporosis patients, were mediated through 
activation of NFKB as evidenced by their suppression in monocyte cultures in the 
presence of SN50, an inhibitor of NFKB while SN50/M, an inactive analogue of 
SN50, failed to show any such effect. Furthermore, NAC, a precursor of in vivo 
antioxidant glutathione, caused suppression of IL-ip secretion and exhibited 
enhancement / amelioration of intramonocyte GSH levels. Interestingly, allicin and 
EGCG showed a higher degree of inhibition of cytokine secretion and enhanced 
antioxidant effect in comparison to NAC, thereby, proving them as effective natural 
herbal antagonists of pathogenesis of osteoporosis. 
Since higher doses of both allicin and EGCG have previously proven to be toxic by 
various investigators, our present study employed lower concentrations (0-500 ng/ml) 
of Allicin as well as that of EGCG (0-20 ng/ml), both of which in their respective 
range of doses, failed to show any toxic effect on human monocytes as revealed by 
MTT assay. Also no effect was observed on human housekeeping gene R18 as, 
revealed by real-time RT-PCR, thereby indicating that allicin and EGCG did not 
non-specifically affect TNF-a and OPG transcription in patient monocytes nor cause 
cellular death. 
Apart from the above, the present study also revealed both allicin and EGCG 
up-regulated the activity of GPx in the monocyte cultures of osteoporosis patients in a 
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dose-dependent manner. The results indicate an appreciable degree of amelioration in 
GPx activity at 500 ng/ml allicin and at 20 M-g/ml EGCG. Significant amelioration of 
GPx activity in osteoporosis patient monocyte cultures indicates reversal of impaired 
neutralizing mechanisms. Similarly, allicin and EGCG were also foxmd to appreciably 
up-regulate the intramonocyte GSH levels in these patients in a dose-dependent 
manner. Interestingly, in comparison to NAC and SN50, allicin and EGCG, both 
exerted more efficient restoration of decreased antioxidant power indicating these 
compounds to be effective herbal antioxidants combating ROS, generated as a 
consequence of excess cellular activation in monocytes of osteoporosis patients. 
Next, it's well established that the Intracellular signaling pathways, especially NFKB, 
are known to be ROS sensitive. Our results indicate that the increased secretion of 
TNF-a, sRANKL and IL-ip at protein levels as well as TNF-a and OPG at the gene i. 
e. mRNA levels, and excess ROS generation as mirrored by decreased GPx activity 
and GSH levels, are interconnected and involve cellular activation of NFKB. This fact 
is evidenced by the suppression of TNF-a, OPG and IL-ip expressions at the protein 
and gene levels and up-regulation of GSH levels in the presence of SN50, an inhibitor 
of NFKB. SN50/M, an inactive analogue of SN50, failed to show any such effect. In 
view of it, our data demonstrate that this effect involved inhibition of NFKB pathway 
induced by allicin and EGCG probably by inhibiting the degradation of iKBa. Since a 
number of genes involved in inflammatory responses are regulated by NFKB pathway, 
thus a high magnitude down-regulation of this pathway by allicin and EGCG would 
predictably reduce the elaboration of NFKB-mediated TNF-a, sRANKL, OPG and 
IL-ip expressions and generation of ROS. 
In conclusion, the presence of high levels of proinflammatory cytokines such as 
IL-1 p, TNF a, sRANKL and a related TNFR super family member OPG together with 
antioxidant deficiency in terms of both low GPx activity and GSH levels and a 
simultaneous increase in MDA levels add to the severity of estrogen deficiency bone 
loss. Our study shows appreciable reversal of impaired neutralizing mechanisms by 
allicin and EGCG which correlates inversely with the down-regulation of TNF a, 
sRANKL, IL-ip, and OPG expressions in monocytes of osteoporotic patients. Thus, 
allicin and EGCG may prove to be valuable natural antioxidant and anti-inflammatory 
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agents in the management of osteoporosis and, therefore, be usefiil adjuncts in the 
treatment of bone loss. These observations strengthen the idea that allicin and EGCG 
should be tested in in vivo models to evaluate their therapeutic potential in the 
pathogenesis of osteoporosis. 
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Abstract 
Abstract 
Osteoporosis is as old as the origin of human civiHzation yet complete understanding 
about it remains to be achieved till date. Osteoporosis and associated fractures 
constitute a major public health issue together representing an important cause of 
mortality and morbidity with annual incidence of fracture rates exceeding the 
combined incidence of breast cancer, stroke and heart attacks in postmenopausal 
women (PMW). Emergence of osteoporosis as a global bone health concern is 
reflected in the occurrence of 1.6 million hip fractures annually worldwide and the 
number projected to go up four times by 2050. Though osteoporosis affects both men 
and women, the later are more susceptible targets of this crippling disorder of bone. 
Osteoporosis has been recognized as that infection, inflammation, and autoimmune 
disorders are associated with systemic and local bone loss. However, it is only recent 
that T lymphocytes and their product have been recognized as key regulators of bone 
cell formation, lifespan and activity. Of many proinflammatory cytokines activated in 
osteoporosis, TNF-a is probably the dominant cytokine, which promotes 
osteoclastogenesis by augmenting the production of RANKL, the non-redundant 
cytokine responsible for osteoclast development. This ability of TNF-a is due to 
synergistic interactions at the level of NF-KB and activator protein-1 (AP-1) signaling. 
Furthermore, THY stimulates osteoclast (OC) activity and inhibits osteoblastogenesis 
thus further driving an imbalance between bone formation and bone resorption. With 
ever increasing number of elderly people in the population, improved survival and an 
increase in the age-specific fracture rates, there is an immediate need to develop new 
cost-effective therapeutic strategies against osteoporosis. Thus, in the present study 
allicin from garlic and EGCG from green tea were employed in order to investigate 
the above. 
Allicin, from garlic is the major biologically active thiosulfinate compound of freshly 
crushed garlic. It has been reported to possess potent antibacterial properties besides 
showing broad range antimicrobial and antifungal activities. Besides, allicin has 
radical scavenging properties in activated granulocytes and may also inhibit iNOS 
expression in activated macrophages. EGCG-a green tea polyphenol, is one of the 
most versatile medicinal plants having a wide spectrum of biological activity. Both 
allicin and EGCG have been reported to have muhiple properties some of which 
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include anti-inflammatory, immunostimulatory, anti-malarial, anti-mycobacterial, 
antipyretic, anticarcinogenic, anti-oxidant and analgesic activities. 
In view of reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
playing an important role in both estrogen related and unrelated osteoporosis, thus, 
greater emphasis now being laid on development of compounds from natural sources 
having antioxidant and anti-inflammatory properties in combating osteoporosis. 
Earlier work in our laboratory has proved the antioxidant and anti-inflammatory 
effects of allicin from garlic in other diseases. Thus, we studied the incorporation of 
such compounds like allicin from garlic, and EGCG- a green tea polyphenol as well 
as a natural antioxidant in the treatment for bone loss. 
The initial phase of the present study undertook a detailed characterization of sera and 
monocytes of osteoporosis patients to assess the activity of predominant antioxidant 
enzyme, GPx and to measure the intramonocyte (GSH) levels. Glutathione (GSH) 
directly reacts with ROS and glutathione peroxidase (GPx) catalyses the removal of 
hydrogen peroxide. ELISA results showed almost less than half the activity of 
enzyme both in sera and monocytes of osteoporosis patients as compared to healthy 
individuals. Decrease in GPx activity therefore, indicates impairment of hydrogen 
peroxide-neutralizing mechanism. A similar suppression in inframonocyte GSH levels 
was observed in these patients indicative of weak antioxidant power. The presence of 
elevated free radicals in osteoporosis patients was also substantiated by MDA 
determination. 
Next, the levels of malondialdehyde (MDA), a by-product of lipid peroxidation were 
observed to be appreciably high both in sera and monocyte cultures of osteoporosis 
patients fiuther pointing to the increased oxidant stress in such patients. Subsequent 
increase in hydrogen peroxide levels due to depressed GSH levels and GPx activity in 
osteoporosis patients might have induced the peroxidation of polyunsaturated fatty 
acids, thereby leading to the formation of high MDA levels. Moreover, due to high 
reactivity of MDA towards amino groups may also lead to deactivation of enzymes. 
Allicin and EGCG dose-dependenfly down-regulated the excess levels of MDA in 
monocyte cultures of osteoporosis patients. 
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Multiple evidences suggest that estrogen prevents bone loss by blocking the 
production of proinflammatory cytokines by bone marrow stromal and bone cells. 
Cytokines regulated by estrogen are IL-1, IL-6 and TNF a. In our study also, probe by 
ELISA showed an appreciable secretion of TNF-a and IL-ip in the sera and 
monocytes of osteoporosis patients. Infact, lL-1 is a potent stimulator of bone 
resorption together with TNF, and both are well-recognized inhibitors of bone 
formation. IL-1 and TNF are also powerful inducers of other cytokines such as IL-6, 
M-CSF and GM-CSF, which potentiate the effect of IL-1 on osteoclastogenesis. 
Next, an attempt was also made to characterize monocytes from osteoporosis patients 
with respect to TNF-a and osteoprotegrin (OPG). Monocytes from these patients were 
subjected to irNF-a and OPG mRNA evaluation by real-time RT-PCR revealing 
appreciably high basal levels of both mRNA expressions. 
The role of OPG in the pathogenesis of osteoporosis has not been clear since OPG 
levels are not consistently altered. In humans, OPG levels increasing with age are 
understood as a homeostatic response to limit the bone loss that occurs wdth an 
increase in other bone resorbing factors. Thus, in the present study, we attempted to 
probe the expression level of OPG and RANKL together with TNF a and their 
regulation by natural antioxidants like allicin from garlic and EGCG from green tea in 
osteoporosis. 
In order to probe the above, in the present study, a real-time RT-PCR was carried out, 
where the data exhibited that both allicin and EGCG down-regulated the expression of 
TNF-a and OPG mRNA in PBMC's of osteoporosis patients in a dose-dependent 
maimer. Concentrations of 250 and 500 ng/ml of allicin and that of 15 ng/ml and 
20 |ig/ml of EGCG respectively were found to suppress the appreciably high basal 
levels of TNF and OPG mRNA's by an appreciable degree. It is to be pointed out that 
previous reports indicated higher doses of allicin were toxic to human cells. Similarly, 
previous reports show that concentrations of EGCG above 23 fig/ml induced 
apoptosis in mononuclear cells. However, our laboratory has shown lower doses of 
allicin (0-500 ng/ml) as well as EGCG (0-20 fig/ml) to be non-toxic and proved to be 
potent anti-inflammatory agent in other disease conditions such as tuberculosis. From 
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our data, it is evident that whereas low concentrations of allicin and EGCG used in 
this study appreciably down-regulate the mRNA expression of TNF a and OPG, at the 
same time show no significant effect on the expression of human housekeeping gene 
R18. Thus, low dose of allicin and EGCG used in the study was non-toxic. 
Although OPG is produced in many tissues, bone derived OPG may be released into 
circulation, thereby reflecting the situation locally in bone. Our results showing 
increased OPG mRNA expression in the osteoporosis patient PBMC's therefore may 
indicate a compensatory response to increased osteoclastic bone resorption and the 
resultant bone loss caused by estrogen deficiency; this considering the fact that OPG 
has bone sparing activity. The expression of OPG mRNA correlated positively with 
that of TNF a mRNA expression. Therefore, OPG, a soluble member of TNFR super 
family of proteins plays an important role in the negative regulation of osteoclastic 
bone resorption. 
Next, as RANKL is necessary for osteoclast differentiation, thus the levels of RANKL 
in monocyte cultures of osteoporosis patients in comparison to healthy controls was 
also probed. Our results showed that in comparison to healthy controls, the patient's 
cultures exhibited around 9-fold augmented levels of RANKL. Thereafter, dose 
response effects of allicin and EGCG showed interesting results. In case of 
osteoporosis patients, sRANKL secretion dose-dependently decreased fi"om 
30.68 pg/ml at through 25.36, 18.12, 9.56 and 4.01 pg/ml with 50, 100, 250 and 500 
ng/ml allicin respectively (P<0.001). Computation of the data revealed that allicin 
down regulated / suppressed the secretion of sRANKL by around 17.34%, 40.93%, 
68.83% and 86.92% with 50, 100, 250 and 500 ng/ml allicin respectively. The IC50 
was computed out to be in between 100-125 ng/ml. Similarly, in case of osteoporosis 
patients, sRANKL secretion was found to dose-dependentiy decrease from 
32.65 pg/ml at through 27.81, 22.45, 17.29, 13.07 and 9.44 pg/ml with 2, 5, 10, 15 
and 20 |ig/ml EGCG respectively. Computational analysis of the data revealed that 
EGCG down regulated / suppressed the secretion of sRANKL by around 14.82%, 
31.24%, 47.04%, 59.96% and 71.08% with 2, 5, 10, 15 and 20 Hg/ml EGCG 
respectively. 1 he IC50 was computed out to be in between 7.5-10 |ig/ml of EGCG. 
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TRAP assay data revealed healthy control monocyte cultures did not show any 
multinucleated cells/osteoclasts, whereas those from osteoporosis patient exhibited 
appreciable number of multinucleated cells/osteoclasts. Interestingly, monocyte 
cultures of 5 days for osteoporosis patient that were co-cultured with 2 ng/ml of 
TNF-alpha exhibited an enhanced number of multinucleated cells/osteoclasts, when 
compared to cultures devoid of any TNF-alpha. Furthermore, in monocyte cultures of 
osteoporosis patient, when co-cultured with 500 ng/ml of allicin and 20 |ig/ml of 
EGCG respectively for 5 days, the TRAP assay data showed that both 500 ng/ml 
allicin as well as 20 |Jg/ml EGCG, inhibited / suppressed / down-regulated the 
formation of multinucleated cells/osteoclasts. The suppression was clearly more in 
cultures receiving allicin in comparison to EGCG. 
Next, secretion of cytokine IL-ip and generation of ROS, as reflected by suppressed 
GPx activity and GSH levels in osteoporosis patients, were mediated through 
activation of NFKB as evidenced by their suppression in monocyte cultures in the 
presence of SN50, an inhibitor of NFKB while SN50/M, an inactive analogue of 
SN50, failed to show any such effect. Furthermore, NAC, a precursor of in vivo 
antioxidant glutathione, caused suppression of IL-ip secretion and exhibited 
enhancement / amelioration of intramonocyte GSH levels. Interestingly, allicin and 
EGCG showed a higher degree of inhibition of cytokine secretion and enhanced 
antioxidant effect in comparison to NAC, thereby, proving them as effective natural 
herbal antagonists of pathogenesis of osteoporosis. 
Since higher doses of both allicin and EGCG have previously proven to be toxic by 
various investigators, our present study employed lower concentrations (0-500 ng/ml) 
of Allicin as well as that of EGCG (0-20 )ig/ml), both of which in their respective 
range of doses, failed to show any toxic effect on human monocytes as revealed by 
MTT assay. Also no effect was observed on human housekeeping gene R18 as 
revealed by real-time RT-PCR, thereby indicating that allicin and EGCG did not 
non-specifically affect TNF-a and OPG transcription in patient monocytes nor cause 
cellular death. 
Apart from the above, the present study also revealed both allicin and EGCG 
up-regulated the activity of GPx in the monocyte cultures of osteoporosis patients in a 
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dose-dependent manner. The results indicate an appreciable degree of amelioration in 
GPx activity at 500 ng/ml allicin and at 20 ^g/ml EGCG. Significant amelioration of 
GPx activity in osteoporosis patient monocyte cultures indicates reversal of impaired 
neutralizing mechanisms. Similarly, allicin and EGCG were also foimd to appreciably 
up-regulate the intramonocyte GSH levels in these patients in a dose-dependent 
manner. Interestingly, in comparison to NAC and SN50, allicin and EGCG, both 
exerted more efficient restoration of decreased antioxidant power indicating these 
compounds to be effective herbal antioxidants combating ROS, generated as a 
consequence of excess cellular activation in monocytes of osteoporosis patients. 
Next, it's well established that the Intracellular signaling pathways, especially NFKB, 
are known to be ROS sensitive. Our results indicate that the increased secretion of 
TNF-a, sRANKL and IL-ip at protein levels as well as TNF-a and OPG at the gene i. 
e, mRNA levels, and excess ROS generation as mirrored by decreased GPx activity 
and GSH levels, are interconnected and involve cellular activation of NFKB. This fact 
is evidenced by the suppression of TNF-a, OPG and IL-ip expressions at the protein 
and gene levels and up-regulation of GSH levels in the presence of SN50, an inhibitor 
of NFKB. SN50/M, an inactive analogue of SN50, failed to show any such effect. In 
view of it, our data demonstrate that this effect involved inhibition of NFKB pathway 
induced by allicin and EGCG probably by inhibiting the degradation of IKBU. Since a 
number of genes involved in inflammatory responses are regulated by NFKB pathway, 
thus a high magnitude down-regulation of this pathway by allicin and EGCG would 
predictably reduce the elaboration of NFKB-mediated TNF-a, sRANKL, OPG and 
IL-ip expressions and generation of ROS. 
In conclusion, the presence of high levels of proinflammatory cytokines such as 
IL-1 (3, TNF a, sRANKL and a related TNFR super family member OPG together with 
antioxidant deficiency in terms of both low GPx activity and GSH levels and a 
simultaneous increase in MDA levels add to the severity of estrogen deficiency bone 
loss. Our study shows appreciable reversal of impaired neutralizing mechanisms by 
allicin and EGCG which correlates inversely with the dovra-regulation of TNF a, 
sRANKL, IL-ip, and OPG expressions m monocytes of osteoporotic patients. Thus, 
allicin and EGCG may prove to be valuable natural antioxidant and anti-inflammatory 
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agents in the management of osteoporosis and, therefore, be useful adjuncts in the 
treatment of bone loss. These observations strengthen the idea that allicin and EGCG 
should be tested in in vivo models to evaluate their therapeutic potential in the 
pathogenesis of osteoporosis. 
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Introduction 
BRIEF BACKGROUND: 
Osteoporosis is a heterogenous metabolic disorder characterized by a progressive loss 
of bone tissue in the increasingly ageing population responsible for the increase in 
bone fragility with a tendency to fracture following minimal trauma. 
Osteoporosis currently affects upto 1 in 3 women and 1 in 12 men at some point in 
their lives (Ligett & Reid, 2000). Approximately 1.6 million hip fractures occur 
worldwide, the incidence is set to increase to 6.3 million by 2050. In India, 1 out of 8 
males and 1 out of 3 females suffers from osteoporosis, making India one of the 
largest affected countries in the world. The number of osteoporotic patients is pegged 
at approximately 26 million (2003 Figures) vwth the numbers projects to increase to 
36 million by 2013 (Sophie et al., 2007). 
CURRENT TREATMENT OF OSTEOPOROSIS AND ITS 
DISADVANTAGES: 
Pharmacological treatments available for osteoporosis are divided into two broad 
categories: 
1. Antiresoptive, which include bisphosphonates, HRT, Selective esfrogen 
receptor modulators (SERMs), calcitonin, vitamin D analogues and 
combination therapy of calcium and vitamin D. 
2. Anabolic, which include sodium fluoride, anabolic steroids and PTH 
(Teriparatide). 
Although currently in use, all have serious disadvantages, for example, the 
bisphosphonates, the most widely used drugs for the treatment of established 
osteoporosis, act by binding to hydroxyapatite and inhibiting osteoclasts at their 
resorption sites and must be taken on an empty stomach. Side effects include nausea, 
vomiting, diarrhoea, peptic ulceration, abdominal pain and constipation along with 
allergic skin reactions and the possibility of osteomalacia (Ferguson, 2004). HRT 
confers an increased risk of pulmonary embolism and breast cancer, and has many 
contraindications (Ferguson, 2004). There is insufficient evidence of benefits, but 
reliable evidence of harm (Bruyere et al., 2003). SERM, for example, raloxifene, acts 
in a similar manner to HRT but with less of a risk of breast cancer, however, still 
carries the risk of venous thromboembolism (Ferguson, 2004). 
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Calcitonin, poly]3eptide hormone produced by the thyroid gland, acts to decrease bone 
resorption by inhibiting the activity of osteoclasts through binding to calcitonin 
receptors on the osteoclast. Side effects include flushing, nausea, vomiting, and 
diarrhoea. Calcitriol (1, 25-dihydroxy vitamin D3) increases intestinal absorption of 
calcium and promotes mineralization of bone. Its efficacy is mainly proven in milder 
cases of osteoporosis whilst side effects include hypercalcaemia and hypercalciuria. 
Anabolic agents increase the number and activity of osteoblasts, but also of 
osteoclasts, resulting in a net increase of bone at cortical sites. Side effects of the drug 
are male characteristics in women, and liver toxicity (Ferguson, 2004). 
PTH acts primarily to sustain or increase plasma calcium levels. PTH has anabolic 
effects on bone, which result from binding to receptors on osteoblast surface, thus 
promoting osteoblast cell proliferation via a signaling pathway involving two second 
messengers (Berne & Levy, 1998). PTH and PTH-related protein (PTHrP), low doses 
of both are the most promising anabolic treatment for osteoporosis thus far however, 
high levels can cause increased bone resorption and osteitis fibrosa cystica 
(Manologas, 2000). Future studies to assess the antifracture efficacy of these 
compounds will be needed before their effectiveness for the management of 
osteoporosis can be established. 
BONE PATHOPHYSIOLOGY: 
Bone is a complex tissue composed of cells, collagenous matrix, and inorganic 
elements. It provides many essential functions, including mechanical support, 
protection of vital organs, a microenvironment for hematopoiesis, and a depot for 
calcium and other minerals. The growth, development, and maintenance of bone are 
highly regulated process (Nijweide et al., 1986). The level of bone mass reflects the 
balance of bone formation and resorption, which at the cellular level involves the 
synthesis of bone matrix by osteoblasts and the coordinate resorption of bone by 
osteoclasts (Felix et al., 1996; Roodman, 1996). Osteoblasts and osteoclasts arise 
from distinct cell lineages and maturation processes; - osteoblasts arise from 
mesenchymal stem cells, whereas osteoclasts differentiate from hematopoietic 
monocytes/macrophage precursors. Both cell types are influenced by a wide variety of 
hormones, inflammatory mediators, and growth factors (Suda et al., 1992; Mundy, 
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1993a, 1993b). An imbalance of osteoblast and/or osteoclast fiinctions can result in 
skeletal abnormalities characterized by increased (osteopetrosis) or decreased 
(osteoporosis) bone mass. 
Low bone mass results due to insuflFicient bone deposited in the skeleton during 
growth or due to subsequent loss of bone tissue at an excessive rate. Several forms of 
osteoporosis have been identified. Osteoporosis can be therefore, classified as primary 
which includes postmenopausal (Type I) or secondary which includes senile (Type II) 
osteoporosis. The Type I variety occurs typically between 55-75 years, affects mainly 
trabecular bone and is more common in women than in men (6:1 ratio). Prior to 
menopause, bone loss occurs at the rate of 0.5-1% per year. At menopause, bone loss 
accelerates at the rate of 2-5% per year due to decline in estrogen levels and is 
greatest in the first 3-6 years post menopause. The Type II or age-related osteoporosis 
occurs after the age of 70 years, affects both cortical and trabecular bone inflicting 
women twice as frequently as men. Secondary osteoporosis can occur due to specific 
causes such as an endocrine disease (e.g., hyperparathyroidism, hyperthyroidism, 
glucocorticoid excess, hypogonadism, etc.), drug induced (e.g., glucocorticosteroids, 
barbiturates, heparin, alcohol, etc.), congenital conditions (e.g., homocystinuria, 
hemolytic anemia, hypophosphatasia, osteogenesis imperfecta), diet conditions (e.g., 
anorexia nervosa, calcium deficiency, malabsorption syndromes, etc.) and 
miscellaneous conditions (e.g., prolonged immobilization, rheumatoid arthritis, 
chronic liver failure, diabetes mellitus, etc.). 
TNF FAMILY MOLECULES IN PHYSIOLOGICAL AND 
PATHOLOGICAL BONE RESORPTION 
a) RANKL. 
Human RANKL [also called TNF-related activation-induced cytokine 
(TRANCE)/ osteoprotegerin ligand (OPGL) /osteoclast differentiation factor 
(ODF)], a cytokine independently discovered by four different groups (Wong et 
al., 1997; Anderson et al, 1997; Yasuda et al.,1998; Lacey et al, 1998), is a 
member of the TNF ligand superfamily. It is a cytokine family that also includes 
TNF- a, FNF- a CD40 ligand. Fas ligand, CD30 ligand, TWEAK, and TRAIL 
Page 3 
Introduction 
(Locksley et al., 2001). Like other members of the TNF-like family of cytokines, 
RANKL is a type II membrane-embedded protein, with a large extracellular 
receptor-binding domain, a membrane-anchoring domain, and a connecting stalk. 
The RANKL gene is present on human chromosome 13ql4 and on mouse 
chromosome 14. The mouse and human RANKL consists of 316 and 317 amino 
acid (aa) residues, respectively. The homology within the TNF ligand family is 
confined to domains involved in monomer folding and trimer assembly. The 
shape of the ligand is that of an inverted bell, which at the base interacts with the 
receptors in 3:3 symmetric complexes. The trimeric protein contains four unique 
surface loops that create the specificity in its interaction with the receptor RANK 
(Lemer, 2004). Like several other TNF-like type D proteins, RANKL trimers 
exist either as membrane-anchored proteins or in a soluble cleaved form, both 
being functionally active (Nakashimu et al., 2000). 
RANKL mRNA is expressed at the highest levels in bone and bone marrow and 
in lymphoid tissues (lymph node, thymus, spleen, fetal liver, and Peyer's patches) 
(Wong et al., 1997; Anderson et al., 1997; Yasuda et al., 1998; Lacey et al., 
1998). Its major role in bone is the stimulation of OC differentiation (Lacey et al., 
1998; Malyankar et al, 2000) and inhibition of OC apoptosis (Fuller et al, 1998). 
In addition, RANKL has a number of effects on immune cells, including 
activation of c-Jun N-terminal kinase (JNK) in T cells (Wong et al., 1997), 
inhibition of apoptosis of dendritic cells (Wong et al., 1997), and alterations in 
cytokine-activated T cell proliferation (Anderson et al., 1997). RANKL knockout 
mice have severe osteopetrosis (Kong et al., 1999) and complete absence of OCs. 
In addition, they exhibit defects in early differentiation of T and B cells, lack 
lymph nodes, and have defects in thymic differentiation and mammary gland 
development (Kong et al, 1999; Fata et al., 2000). The promoter region of the 
RANKL gene contains a response element for core-binding factor al (Cbfa-1 or 
Runx2) which is a transcription factor crucial for OB differentiation and 
expression of bone matrix proteins (Ducy et al., 1997) 
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b) RANK: 
Receptor activator of nuclear factor kappa B (RANK), a member of the TNF 
receptor superfamily, is a type E transmembrane protein containing four 
cysteine-rich pseudorepeat domains in the extracellular region, a hallmark of the 
TNF-R family (Locksley et al., 2001). The mouse and human RANK contain 625 
and 616 aa residues, respectively, the latter having a signal peptide (28 aa), an 
N-terminal extracellular domain (184 aa), a transmembrane spanning domain 
(21 aa), and a large C-terminal cytoplasmic tail (383 aa). In the human genome, 
RANK is present on chromosome 18q22.1. The extracellular part of TNF-R-like 
receptors forms elongated structures by a scaffold of disulfide bridges, which fit 
into the inverted bell/ groove of the ligand trimer in a 3:3 complex 
(Locksley et al., 2001). This has recently been demonstrated to be true for the 
interaction between RANKL and RANK (Lam et al., 2001). Although RANK is 
ubiquitously expressed in human tissues, its cell surface expression is limited to 
DC, the CD4+ T cell line MP-1, foreskin fibroblasts, OC precursors, and certain 
Hodgkin lymphomas (Anderson et al., 1997; Hsu et al.,1999; 
Fiumara et al., 2001). RANK knockout mice lack peripheral lymph nodes and 
have defective T and B cell maturation (Li J et al., 2000). 
c) OPG: 
Osteoprotegerin (OPG); also knovm as osteoclastogenesis inhibitory factor 
(OCIF) or TNF receptor-like molecule (TR 1), is a secreted protein that regulates 
bone mass by inhibiting OC differentiation and activation (Simonet et al., 1997; 
Yasuda et al., 1998; Tan et al., 1997). OPG is synthesized in humans, rats, and 
mice as a 401-aa protein, which, after cleavage of 21-aa signal peptide, results in 
a 380-aa mature protem. In humans, the OPG gene is located on chromosome 
8q23-24. The aa sequence of OPG displays several homologies to members of 
the TNF-R superfamily, including RANK. The 60-kDa monomer OPG protein 
forms 120-kDa disulfide-linked homodimers containing several N-glycosylation 
sites. OPG contains four cysteine-rich domains in the N-terminal end, two 
homologous 'death domains' (DDH) in the C-terminus, a heparin-binding site, 
and a cysteine residue required for homodimerisation but, in contrast to other 
members of the TNF-R superfamily, lacks a transmembrane spanning domain 
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and a cytoplasmic tail. Secreted OPG acts as a 'decoy receptor' due to its affinity 
to both membrane-bound and soluble RANKL and prevents the activation of 
RANK. OPG mRNA has been detected in bone, cartilage, aorta, skin, lung, heart, 
kidney, liver, brain, and in several other tissues. At the cellular level, OPG is 
expressed in OBs, stromal cells, endothelial cells, aortic smooth-muscle cells, 
fibroblasts, dendritic cells, and lymphoid cell lines (Lemer, 2004). 
Osteoclast precursors Mature osteoclasts 
^^teoblasts/Sgonglcell^B 
RANKL Ch RANK DIFFERENTIATION 
RANKL OPG 
•decoy r«<»p<or* 
INHIBITION 
Figure (a): The RANK/RANKL/OPG System 
RANKL, expressed on the cell surface of osteoblasts/stromal cells, binds to RANK, 
expressed on the cell surface of hemopoietic osteoclast precursor cells, inducing a 
signaling and gene expression cascade that leads to their differentiation and 
maturation to osteoclasts. OPG, which can bind to RANKL, acts as a decoy receptor, 
blocking the interaction between osteoblasts/stromal cells and the osteoclast 
precursors, thereby inhibiting osteoclast formation. (Adapted from medscape.com) 
Page 6 
Introduction 
CLINICAL UTILITY OF BIOCHEMICAL MARKERS OF BONE 
REMODELING: 
Bone is a metabolically active tissue that undergoes continuous remodeling by two 
counteracting processes, namely bone formation and bone resorption. These processes 
rely on the activity of osteoclasts (resorption), osteoblasts (formation) and osteocytes 
(maintenance). Under normal conditions, bone resorption and formation are tightly 
coupled to each other, so that the amount of bone removed is always equal to the 
amount of newly formed bone [Figure (b)]. This balance is achieved and regulated 
through the action of various systemic hormones (e.g. PTH, vitamin D, and other 
steroid hormones) and local mediators (e.g. cytokines, growth factors). In contrast, 
somatic growth, ageing, metabolic bone diseases, states of increased or decreased 
mobility, therapeutic interventions and many other conditions are characterized by 
more or less pronoimced imbalances in bone turnover. 
Although the currently available markers of bone turnover include both enzymes and 
non-enzymatic peptides derived from cellular and non-cellular compartments of bone, 
they are usually classified according to the metabolic process they are considered to 
reflect. Most biochemical indices of bone resorption are related to collagen 
breakdown products such as hydroxyproline or the various collagen cross-links and 
telopeptides. Other markers of bone resorption include non-collagenous matrix 
proteins such as bone sialoprotein (BSP), or osteoclast-specific enzymes like 
tartrate-resistant acid phosphatase or cathepsin K. In contrast, markers of bone 
formation are either by-products of collagen neosynthesis (e.g. propeptides of 
type 1 collagen), or osteoblast-related proteins such as osteocalcin (OC) and alkaline 
phosphatase (AP). For clinical purposes, therefore, markers of bone formation are 
distinguished from indices of bone resorption [Figure (c)]. This distinction, however, 
is not as sharp as it may appear. For example, some marker components reflect, at 
least in part, both bone formation and bone resorption (e.g. hydroxyproline, 
certain OC fragments). Furthermore, most of the molecules used as markers of bone 
turnover are also present in tissues other than bone, and non-skeletal processes may 
therefore influence their circulating or urinary levels. Finally, changes in markers of 
bone turnover are not disease specific but reflect, as an integral measure, alterations in 
the metabolism of the entire skeletal envelope independently of the underlying cause. 
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Hence, results of bone marker measurements should always be interpreted against the 
background of their basic science and the clinical picture. 
IVIineralisation Oslcobliuts y'i\ 
MDDDD^ 
Minvrafiscd Bone 
Multinuclcar 
Oslcoclatt 
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Ruffled 
border 
Resorption pit 
Osteoid 
Formation 
Figure (b): The bone remodelling cycle 
Under normal conditions, the resorption (osteoclast) phase takes approximately 10 
days, which is then followed by a formation (osteoblast) phase that can last for up to 3 
months. (Adapted from Seibel MJ, 2005) 
Page 8 
Introduction 
Formation 
BAP 
Collagen type i 
propeptides 
Osteocalcin 
Resorption 
Calcium 
TRAcP 
BSP 
Hydroxyproline 
Hydroxylysine glycosides 
Pyridinium crosslinks 
Collagen type I 
telopeptides 
Osteoblasts Bone matrix Osteoclasts 
Figure (c): Biochemical markers of bone remodelling (Adapted from Seibel MJ, 
2005) 
1. BONE FORMING MARKERS: 
a) Alkaline phosphatase 
Osteoblasts are rich in alkaline phosphatase; however, alkaline phosphatase, an 
enzyme associated with the plasma membrane of cells, is also found in liver, 
intestine, and placenta (Gomez B, Jr, Ardakani S, Ju J, et al., 1995), all of which 
may contribute to the total amount of alkaline phosphatase found in blood. The 
bone isoenzyme predominates in childhood and particularly during puberty; 
however, in adults the bone and liver isoenzymes contribute approximately 
equally to the total, with the intestinal fraction accounting for <10%. The 
function of alkaline phosphatase is unknown. The condition hypophosphatasia, in 
which the enzyme is lacking, is characterized by osteomalacia, suggesting that 
alkaline phosphatase has a role in the mineralization of newly formed bone. 
Measurement of total serum alkaline phosphatase is useful when the amount from 
bone is exceptionally high (such as in Paget disease of bone) and concentrations 
from other sources are not increased and are stable. Because of the multiple 
sources of origin and the fact that the bone isoform is usually not increased in 
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osteoporosis and other metabolic bone diseases, total alkaline phosphatase has 
not enjoyed vsddespread use as a bone remodeling marker. 
Bone, liver, and intestinal isoforms of alkaline phosphatase are posttranslational 
modifications of the same gene product and can be identified by their unique 
carbohydrate content (Martin M et al., 1997). Measurement of "fractionated" 
alkaline phosphatase recognizes that heating destroys the skeletal fraction, which 
can be determined by subtraction of the stable fraction from the total. This 
procedure is not sufficiently reproducible to be used clinically. Assays for bone 
alkaline phosphatase [BAP; also known as bone-specific alkaline phosphatase, or 
skeletal alltaline phosphatase (SAP)] have been developed using electrophoresis, 
isoelectric focusing, lectin precipitation, and immunoassay techniques. 
Immunoas.say is the method of choice because of high specificity and satisfactory 
precision. Commercially available immunoassays have been developed that 
measure either enzyme activity or mass (Woitge H et al., 1996; Van Straalen JP 
et al., 1991; Alpers DH et al., 1984). Because BAP is cleared by the liver, the 
skeletal fraction may be increased in patients with liver diseases. There may also 
be some cross-reaction of BAP antibodies with liver alkaline phosphatase. 
b) Osteocalcin 
Osteocalcin, the major noncollagen protein of bone matrix, is a small 49-amino 
acid protein that is rich in glutamic acid (GLA) (Farley JR et al., 1981). 
Osteocalcin is also known as bone GLA protein and BGP. In addition to bone, it 
is also found in dentin. The fimction of osteocalcin is not clear; it may serve as a 
site for hydroxyapatite crystals. In the process of matrix synthesis, some 
osteocalcin is released and circulates in blood v^ dth a short half-life determined 
mainly by renal clearance. Although no intact osteocalcin is released during bone 
resorption, fragments are released in vitro and also during resorption and 
formation (Gorman L & Statiand BE, 1997; Gallop PM et al., 1980; Hauschka 
PV et al., 1989). Osteocalcin can be measured by immunoassay in plasma or 
serum. Osteocalcin is labile in blood. It is reduced in lipemic serum because of 
binding of osteocalcin to lipids, and osteocalcin may be degraded in vitro by 
proteolytic enzymes liberated from erythrocytes. Assays for osteocalcin are not 
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standardized (Gundberg CM et al., 1999), and different antibodies clearly 
recognize different fragments (Price PA et al., 1987; Ducy P et al., 1996). 
Antibodies that recognize both the intact molecule and the large N-terminal mid 
molecule fragment appear to provide the best clinical information (Brown JP et 
al., 1984) 
Although vitamin K status does not affect the total-osteocalcin concentration, it 
does affect the amount of carboxylation. Undercarboxylated osteocalcin may be a 
better predictor of certain outcomes such as fracture (Bouillon R et al., 1992; 
DelmasPDetal., 1983). 
c) Procollagen extension peptides 
Osteoblasts secrete large procollagen molecules that undergo exfracellular 
cleavage at the amino and carboxy termini. Byproducts of type 1 collagen 
synthesis are the amino- and carboxy-terminal procollagen 1 extension peptides 
(PINP and PICP) (Crofton PM, 1992; Gundberg CM et al., 1985; 
Taylor AK et al., 1988; Monaghan DA et al., 1993; Parviainen M et al., 1994). 
PINP is an elongated protein of 35 kDa. PICP is a globular protein of 1000 kDa 
and contains disulfide bodes. Both extension peptides are cleared by the liver. 
Both may be incorporated into bone matrix. Both can be measured by 
immunoassay. The concentrations of both increases with increased turnover of 
nonskeletal collagen (e.g., skin and muscle). 
2. BONE RESORBING MARKERS: 
Bone resorption markers include an enzyme, tartrate-resistant acid phosphatase 
(TRAP), and products of bone breakdown, which include calcium and bone 
matrix degradation products such as hydroxyproline, pyridinium cross-links, and 
telopeptides. Urinary calcium is affected by diet and renal function and is not 
sufficiently sensitive or specific for assessment of bone remodeling. 
a) TRAP 
Acid phosphatase is a lysosomal enzyme found in bone, prostate, platelets, 
erythrocytes, and spleen. Of the five isoenzymes of acid phosphatase, the bone 
isoform is tartrate resistant (TRAP) but unstable. TRAP can be measured in 
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serum or plasma by electrophoresis (after treatment with tartrate) or by 
immunoassay. Serum acid phosphatase concentrations are typically higher than 
those in plasma because of the release of acid phosphatase from erythrocytes 
during clotting. 
b) Collagen breakdown products 
Type 1 collagen, rich in the amino acid hydroxyproline, has a triple helix 
structure, with strands connected by cross-links between lysine or hydroxylysine 
residues that join the non helical amino- and carboxy-terminal ends of one 
collagen molecule to the helical portion of an adjacent molecule. (Lian JB et al., 
1999). The cross-links are pyridinolines and deoxypyridinolines. During bone 
resorption, hydroxyproline and the pyridinium cross-links may be released either 
free or with fragments of the collagen molecule attached. They are not reutilized. 
Although some type 1 collagen is present in non skeletal tissues, bone has a much 
higher proportion and a much higher turnover. 
c) Hydroxyproline 
Collagen is rich in the amino acid proline, which undergoes postfranslational 
hydroxylation to hydroxyproline. Most of the free hydroxyproline liberated from 
bone is catabolized in the liver; ~10% is released in small polypeptide chains that 
are excreted in the urine. Hydroxyproline is also liberated by the breakdown of 
complement and nonskeletal collagen, including dietary collagen, and by the 
breakdown of procollagen extension peptides, which are products of bone 
formation. Approximately 50% of urinary hydroxyproline is derived from bone 
collagen breakdown (Rizzoli R et al., 1999). Hydroxyproline is usually measured 
in urine by colorimetry or HPLC after hydrolysis to convert peptide and 
polypeptide forms to the free form. 
d) Pyridinium cross-links (pyridinoline and deoxypyridinoline) 
Posttraiislational modification of lysine and hydroxylysine produces the 
nonreducible pyridinium cross-links, pyridinoline (Pyr) and deoxypyridinoline 
(Dpd), that stabilize mature collagen. Both Pyr and Dpd are released from bone 
in a ratio of approximately 3:1. Dpd is relatively specific for bone; Pyr is also 
found in articular cartilage and in soft tissues (ligaments and tendons). 
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Approximately 60% of the cross-links released during resorption are bound to 
protein, with the remaining 40% being free (not protein bound). Pyridinium 
cross-linlcs are not metabolized or absorbed from the diet (3). Pyr and Dpd can be 
measured in urine by HPLC or immunoassay (Stinson RA & Hamilton BA, 
1994; Harris H, 1980; Crofton PM, 1982; Koyama 1 et al, 1987; Langlois MR et 
al., 1994; Green S et al., 1971) either before or after hydrolysis. 
e) Cross-linked telopeptides 
In the process of bone resorption, amino- and carboxy-terminal fragments of 
collagen are released with cross-links attached. These fragments with attached 
cross-links are called telopeptides. N-telopeptides (NTx) and C-telopeptides 
(CTx) c'lre excreted in the urine. NTx is measured by immunoassay using an 
antibody to the a-2 chain of the NTx fragment (which contains the pyridinium 
cross-links, but the assay does not recognize the cross-link itself) 
(Van Hoof VO et al., 1990). CTx is measured by immunoassay (Magnusson P et 
al., 1999). Urine has been the most convenient sample for assay, but efforts have 
been directed at developing serum assays (Hill CS & Wolfert RL, 1989; Rosaiki 
SB & Foo AY, 1984; Rosaiki SB & Foo AY, 1987; Crofton PM, 1992) 
f) Cathepsin K 
Cathepsin K is a member of the cysteine protease family that, unlike other 
cathepsins, has the unique ability to cleave both helical and telopeptide regions of 
collagen I. fts clinical relevance was appreciated with the discovery that 
pycnodysostosis, an autosomal recessive disease characterised by osteopetrosis, 
was the result of mutations in the cathepsin K gene. This clinical phenotype has 
been confirmed in cathepsin K null mice showing dysfiinctional matrix digestion. 
Immunocytochemical studies have shown that cathepsin K is located 
intracellularly in vesicles, granules and vacuoles throughout the cytoplasm of 
osteoclasts and that it is secreted into bone resorption lacunae for exfracellular 
collagen degradation. Recently, a new enzyme-linked immunoassay for 
measurements of cathepsin K in serum has been developed. Due to the fact that 
cathepsin K is expressed and secreted by osteoclasts during active bone 
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resorption, cathepsin K, and specifically its circulating form, may be a useful and 
specific biochemical marker of osteoclastic activity (Seibel MJ, 2005) 
ROLE OF NITRIC OXIDE (NO) IN BONE REMODELING 
NO, an intracellular messenger stimulated by PTH and 1, 25-dihydroxyvitamin D3 
has complex effects on bone cells. Earliest studies have linked NO to bone 
remodeling whereby inhibition of ON synthase(NOS), the enzyme that synthesizes 
NO from L-arginine potentiated ovariectomised bone resorption in rats. 1 .NO potently 
suppresses RANKL expression in both primary murine stromal cells and a stromal 
cell line, ST-2 while up-regulates OPG expression. Low concentrations of NO donors 
(SNP, NOR-4) have significant effects on both mRNA and protein levels of RANKL 
and OPG. Besides, NO, other osteoactive factors are known to effect similar 
co-ordinate changes in RANKL and OPG expression like PTH and IGF-1 stimulates 
RANKL mRNA expression, while also decreasing OPG expression (Lee and 
Lorenzo., 2002; Rubin et al., 2002). TGF-al, similar to NO, decreases RANKL while 
increasing OPG (Takai et al., 1998). Because of the universality of NO signaling, it 
may be that some of these factors regulate RANKL/OPG ratios through modulating 
NOS activitj^  in bone cells. NO can influence their transcription through structural 
modifications of transcription factors, for instance changing the binding affinities of 
c-Fos, c-Jun, or NF-kB by S-nitrosylation of cysteines near their DNA-binding 
domains (Mijrshall et al., 2000; Nikitovic et al., 1998; Tidball et al., 1999). 
NO is constitutively produced in OBs whereby it can be an effective mediator to 
regulate OB proliferation and differentiation (O'Shaughnessy et al., 2000). However, 
over expression of NO leads to OB injuries (Damoulis and Hauschka., 1997; Mancini 
et al., 2000; Mogi et al., 1999). NO can damage OB DNA and induce cell apoptosis 
(Chen et al, 2004).Besides, SNP, an NO donor, can decrease mitochondrial 
membrane potential of OBs consequently decreasing cellular ATP levels. SNP 
enhances release of intracellular ROS and cytochrome c from mitochondria to 
cytoplasm. Reduction of ATP synthesis (Blom et al., 2003) and enhancement of ROS 
(Mancini et al., 2000) induce cell apoptosis as is evidenced by suppression of 
Bcl-2/Bax proteins following SNP treatment of Osteoblasts. Thus, the NO-induced 
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death of osteoblastic cells has been shown to occur via an apoptotic pathway 
(Chen et al., 2004). 
SIGNALING PATHWAYS IN OSTEOCLASTOGENESIS 
Recognition and binding of the RANK by RANKL is the key osteoclastogenic event, 
inducing a number of parallel signaling cascades. Three important pathways in 
osteoclastogenesis are described below, which are (a) NF-kB activation pathway, 
(b) c-Jun signaling pathway and (c) The calcineurin / NFAT signaling pathway. The 
details are as under: 
a) NF-kB ACTIVATION PATHWAY 
RANK activation by RANKL is followed by its interaction with TNF receptor-
associated factors (TRAP) family members TRAF2, TRAF3, TRAF5, and 
TRAF6 (Wong et al.,1998; Damay et al., 1998; Damay et al.,1999; Damay et al., 
1999) which in turn recruits NF-kB inducing kinase leading to the activation of 
NF-kB (Damay et al., 1999). TRAF6 and NF-kB play an indispensable role in 
OC differentiation as demonstrated by the osteopetrotic phenotype of TRAF6 and 
NF-kB knockouts (Lomaga et al., 1999; lotsova et al., 1997). 
NF-kB is a dimer consisting of the NF-kb / Rel family proteins which 
include p50, p52, p65, c-Rel, and Rel-B. In the unstimulated cells, NF-kB dimer 
in cytosol is present as an inactive form complexed with an inhibitory protein 
IkB, two major forms of which are IkB-a (Haskill et al.,1991) and IkB- a 
(Thompson et al.,1995). When stimulated by stimulatory cytokine, TNF- a, the 
NF-kB dimer dissociates from IkB and translocates to the nucleus, the process 
being called 'activation of NF-kB'. The activated NF-kB dimer binds to the 
regulatory NF-kB elements in the target genes and regulates their transcription 
(Baeuerle & Hankel, 1994). 
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Figure (d): A schematic representation of osteoclast differentiation 
Osteoclast differentiation supported by RANKL binding with RANK. The RANK 
signaUng is transduced via TNF receptor-associated factor 2 (TRAF2) and TNF 
receptor-associated factor 6 (TRAF6) leading to the activation of NF-Kb, which in 
turn stimulates the activation and differentiation of osteoclasts. (Adapted from 
Udagawa, 2002) 
b) c-Jun SIGNALING PATHWAY 
RANKL is unique among TNF ligand superfamily members in its capacity to 
induce OC differentiation. The mechanism probably involves its interaction with 
TRAF6 (Lomaga et al., 1999). Association of RANKL and TRAF6 activates key 
events involving activator protein-1 (AP-1) mediated transcription of OC specific 
genes. The importance of AP-1 transcription factors, especially dimers of the Fos 
and Jun families of proteins, in the osteoclastogenic process was first 
documented by Erwin Wager wherein c-Fos knockout mice were shown to be 
osteopetrotic due to complete absence of OCs (Grigoriadis et al., 1994). RANK 
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occupancy mobilizes intracellular calcium, a requisite for calcineurin-mediated 
nuclear factor of activated T ceils (NFAT) activation. Moreover, RANKL not 
only induces the transcription factor's expression but facilitates its nuclear 
translocation, where NFAT binds to its DNA response element via a ternary 
complex with AP-1 proteins, including Fos/Jun, to transactivate target genes 
(Macian et al., 2001). Thus, RANKL-induced osteoclastogenesis involves 
partnering of Fos / Jun with NFAT2. NFATl functions as the upstream regulator 
for NFAT2 during osteoclastogenesis and c-Jun is necessary for NFATl to 
induce NFAT2 expression as demonstrated by recent studies that RANK induced 
NFAT2 expression in bone marrow macrophages (BMM) or RAW264.7 cells 
promoting their differentiation into TRAP+ osteoclast-like cells even in absence 
of sRANKL (Ishida et al., 2002; Takayanaki et al., 2002). Besides, over 
expression of NFATl, which is expressed in OC progenitors and mature OCs, 
induces expression of NFAT2 and OC differentiation of RAW264 cells 
(Ikeda et al., 2004). The partnership between c-Jun / c-Fos and the NFAT family 
has been shown to be crucial for OC differentiation by enhancement of the 
osteoclastogenic activity of NFATl and NFAT2 by over expression of c-Jun and 
c-Fos while inhibition by over expression of either dominant negative c-Jun or 
c-Fos (Ikeda et al., 2004). 
(c) CALCINEURIN / NFAT SIGNALING PATHWAY 
Calcineurin is best known for its role during T cell activation, where it acts to 
regulate the activity of the nuclear factor of activated T cells (NFAT) family of 
transcription factors and thereby couples stimulation of the T cell 
antigen-receptor to changes in the expression of cytokines and other important 
immunoregulatory genes (Rao et al., 1997; Crabtree et al., 2002). In T cells, 
calcineurin is activated in response to the T cell receptor-induced increase in the 
intracellular calcium concentration. Once activated, calcineurin directly 
dephosphorylates NFAT proteins that are present in a hyperphosphorylated latent 
form in the cytoplasm and induces their rapid translocation into the nucleus, 
where in concert with nuclear partner proteins such as activator protein-1 (AP-1) 
transcription factor complex, they are able to bind cooperatively to their target 
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promoter elements and activate the transcription of specific NFAT target genes 
(Rao et al., 1997; Crabtree et ah, 2002). 
RANK stimulation can activate calcium dependent signaling events via the 
effects of the Src tyrosine kinase on phospholipase C (Kim et al., 2002). The Src 
tyrosine kinase is coupled to RANK via its interaction with the cytoplasmic 
adaptor protein, TRAF-6 (Lomaga et al., 1999). RANK-induced activation of Src 
is likely to affect the activity of the calcineurin / NFATcl signaling pathway in 
two distinct ways. First, the TRAF-6 / Src-dependent activation of phospholipase 
C and the subsequent production of the calcium mobilizing agent inositol 
triphosphate lead to an increase in the intracellular calcium concentration which 
in turn presumably activates calcineurin, thereby inducing dephosphorylation of 
NFATcl and its rapid transport into the nucleus. Second, the 
TRAF-6 / Src-dependent activation of protein kinase B likely results in the 
phosphorylation and subsequent inhibition of the principal NFATcl inhibitory 
kinase, glycogen synthase kinase-3, thereby preventing this kinase from directly 
phosphorylating active NFATcl (Beals et al., 1997; Neal and Clipstone., 2001). 
Enforced expression of an activated NFATcl "allele in RAW264.7 cells is 
sufficient to minimize the effects of the RANKL stimulation and induce these 
cells to acquire a morphologically distinct, TRAP-positive, multinucleated 
osteoclast-like bone resorbing phenotype (Hirotani et al., 2004). caNFATcl is 
also able to induce the expression of a panel of genes including TRAP, cathepsin 
K, the calcitonin receptor, and the and integrin subunits, which together are 
considered to be molecular markers of fully differentiated Osteoclasts 
(Teitelbaum, 2002; Suda et al., 1995; Lee et al., 1995; Quinn et al., 1999; Tong et 
al., 1994) 
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Figure (e): Signaling cascades during osteoclastogenesis. 
Receptor activator of nuclear factor-KB ligand (RANKL)-RANK binding results in 
the recruitment of tumor necrosis factor receptor-associated factor 6 (TRAP 6), which 
activates nuclear factor-KB (NF-KB) and mitogen-activated protein kinases. RANKL 
also stimulates the induction of c-Jun through NF-KB. NF-KB and c-Jun are important 
for the robust induction of nuclear factor of activated T cells cytoplasmic 1 
(NFATcl). RANK signaling further activates calcium dependant signaling via Src 
tyrosine kinase, the latter of which is critical for the activation and auto amplification 
of NFATcl. (Adapted from Okamoto & Takayanagi, 2011). 
MODULATION OF BONE CELL ACTIVITIES BY TNF- a 
TNF- a is a member of the TNF ligand superfamily, and is secreted by many cell 
types including monocytes/macrophages and OBs. At cellular level, TNF- a 
modulates a broad spectrum of responses, including inflammation, immunoregulation, 
proliferation, differentiation, and apoptosis (Ledgerwood et al., 1999). TNF- a 
induces these responses via two cell-surface receptors termed TNFRl and TNFR2 
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(also called TNFRp55 and TNFRp75, respectively) (Lewis et al., 1991; Tartaglia & 
Goeddel, 1992). Both receptors transduce intracellular signals that stimulate the 
proteolytic breakdown of inhibitor of kappa B (leB), a cytoplasmic inhibitor of NF-eB 
(Baldwin., 1996; Verma et al., 1995). TNF- a is known to promote bone resorption in 
vitro and in vivo (Bertolini et al, 1986; Kitazawa et ah, 1994; Thomson et al., 1987; 
Lemer and Ohlin, 1993) and induce secretion of RANKL in osteoblastic cells 
(Hofbauer et al., 1999). TNF- a also plays an important role in E deficiency induced 
bone loss in postmenopausal osteoporosis(Kimble et al., 1996; Kimble et al., 1997; 
Cenci et al., 2000). TNF-a alone or in combination with IL-1 contributes to the 
increased numbers of OCs seen at sites of bone resorption. Its been recently shown 
that colony stimulating factors such as IL-3 and granulocyte macrophage colony 
stimulating factor (GM-CSF) inhibit RANKL-induced OC differentiation by direct 
action on OC precursors (Khapli et al., 2003; Miyamoto et al., 2001). IL-3 inhibits 
RANKL-induced OC differentiation, by down-regulation of c-Fos expression and 
prevention of NF-kB signaling, and diverts the cells to macrophage lineage; whereas, 
GM-CSF inhibits RANKL-induced OC differentiation by inhibiting c-Fos expression, 
and diverts the cells to dendritic cell lineage (Yogesha et al., 2005). Using stromal and 
lymphocyte-free cultures of OC precursors, and whole bone marrow cells, Yogesha 
and group, show that IL-3 and GM-CSF act directly and irreversibly on OC 
precursors by significantly inhibiting c-Fms post transcriptionally. Development and 
expansion of OC precursors is c-Fms dependent. Both colony stimulating factors 
completely inhibit TNF- a -induced OC formation via action on TNFRs. TNFRl and 
TNFR2 differentially impact osteoclastogenesis. It has been reported that TNF-a 
stimulates OC formation in TNFR2-/- but fails to stimulate osteoclastogenesis in 
TOFRl-/- mice (Abu-Amer et al., 2000; Roggia et al., 2001). IL-3 and GM-CSF have 
been shown to inhibit OC differentiation by down regulation of mRNA and surface 
expression of both TNFRl and TNFR2 in OC precursors as well as whole bone 
marrow cells suggesting that IL-3 and GM-CSF down-regulate expression of TNFRl 
and TNFR2 at transcriptional and translational levels in the presence or absence of 
neighboring cells (Yogesha et al., 2005). 
TNF- a exerts pleiotropic effects on OBs or osteoblast-like cells such as inhibition of 
DNA and collagen synthesis (Nanes et al, 1989) and osteocalcin gene expression 
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(Nanes et al., 1991; Kuno et al., 1994) and stimulation of synthesis of proteolytic 
enzymes such as plasminogen activators and matrix metalloproteinases (Panagakos & 
Kumar., 1994) and cytokines such as IL-8(Chaudhary et al., 1992). TNF- a increases 
mRNA levels of IL-6 and lCAM-1 genes in the rat osteoblast-like osteosarcoma cells 
(ROS 17/2.8 cells) while an antioxidant, N-acetyl cysteine (NAC) inhibits the 
p50-p65 heterodimer activation of NF-kB indicating that generation of reactive 
oxygen intermediates (ROl) mediates the TNF- a -dependent activation of NF-kB in 
ROS 17/2.8 cells. Simultaneously, NAC attenuated the TNF- a -dependent increase in 
the mRNA levels for both IL-6 and ICAM-l(Kurocouchi et al., 1998). lL-6 stimulates 
both proliferation and differentiation of the OC precursor cells (Roodman, 1993) and 
also promotes the B cell proliferation and differentiation, and activate T ceils (Hirano 
et al., 1986; Houssiau & Van., 1992). 
MODULATION OF BONE CELL AVTIVITIES BY ESTROGEN 
A network of estrogen (E) regulated cytokines is responsible for the changes in bone 
turnover and tlie loss of bone induced by E-deficiency. Considerable evidence has 
accumulated that suggests that Estrogen prevents bone loss by blocking the 
production of proinflammatory cytokines by bone marrow and bone cells 
(Pacifici, 1996; Manolagas &. Jilka, 1995). The main consequence of increased 
cytokine production in the bone microenvironment is an increased osteoclast (OC) 
formation and elongation of their life span (Roodman, 1996). In addition, enhanced 
cytokine production results in increased activity of mature OCs and an increased 
osteoblastic activity which compensates only in part the increased rate of bone loss. 
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Figure (f): Overview of tlie multiple interactions by which cytokines and 
estrogen regulate bone resorption. 
The arrows indicate stimulatory {[) or inhibitory (-^ ) effects of a cytokine on the 
synthesis of another cytokine or on a particular step in osteoclastogenesis. Estrogen 
plays a negative effect on the increased cytokine production of IL-1, IL-6 and TNF-a, 
thus maintaining a healthy bone microenvironment. (Adapted from Pfeilschifter J, 
2002) 
(a) CYTOKINE PROFILE IN ESTROGEN DEFICIENCY BONE LOSS 
Among the cytokines known to be regulated by E are IL-1, IL-6, and TNF 
(Pacifici, 1996; Manolagas & Jilka, 1995).IL-1 and TNF are the most powerful 
locally produced stimulators of bone resorption and are well recognized 
inhibitors of bone formation. IL-1 and TNF activate mature OCs indirectly via a 
primary effect on osteoblasts (OBs) and inhibit OC apoptosis. Besides, they 
markedly enhance OC formation by stimulating the proliferation of 
OC precursors both directly and by enhancing the pro-osteoclastogenic activity 
of stromal cells.IL-1 and TNF are also powerful inducers of other cytokines that 
regulate the differentiation of OC precursor cells into mature OCs such as IL-6, 
M-CSF and GM-CSF. IL-6 is a potent osteoclastogenic factor that exerts its 
effects via a cell surface receptor that consists of a ligand binding chain (IL-6R) 
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and a signal transducing chain known as gpl30. When bound to soluble IL-6R, 
lL-6 stimulates the early stages of osteoclastogenesis in human and murine 
cultures, presumably by forming a complex with gpl30 expressed on either 
stromal cell or OBs (Udagawa et al., 1995). IL-6 is more potent in increasing the 
formation of OCs from hemopoietic precursors than in activating mature OCs 
(Lowik et al., 1989; Roodman GD, 1993). 
11-7 is an osteoclastogenic cytokine, the principal sources of which are the bone 
marrow, stromal cells (Fry & Mackall, 2002) and OBs (Weitzmann et al, 2000). 
lL-7 promotes osteoclastogenesis by up-regulating key T cell- derived 
osteoclastogenic cytokines, including receptor activator of nuclear factor kappa B 
(NF- kB) ligand (RANKL) (Weitzmann et al., 2000). IL-7 also increases the 
number of early precursors of the B cell lineage (B220+ cells) in the bone 
marrow (Miyaura et al., 1997), a population that has been suggested to have the 
capacity to differentiate into OCs (Sato et al., 2000). Thus, IL-7 may also induce 
bone loss by increasing the pool of OC precursors. Upregulation of IL-7 which is 
a consequence of E2 deficiency has been shown to play a central role in 
ovx-induced bone loss by uncoupling bone formation from bone resorption 
(Weitzmarm et al., 2002) whereby IL-7 treatment of osteoblastic cells led to a 
decrease in the promoter activity of Cbfal/Runx2. This ultimately leads to a 
decrease in the protein concentration of Cbfal/Runx2 and hence reduced 
transact!vation of Cbfal/ Runx2 responsive promoters. Cbfa/Rimx2 is both a 
marker of and a key participant in the process of OB differentiation. IL-7 
stimulates osteoclastogenesis fiirther through down regulation of OPG, the decoy 
receptor of RANKL, due to reduction of Cbfal/ Runx2 levels. Therefore, IL-7 is 
a relevant causal agent of bone loss induced by E2 withdrawal, as the stimulatory 
effect of IL-7 on bone resorption is compounded by the inhibition of bone 
formation (Weitzmann et al., 2002). 
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Figure (g): Osteoclastogenesis and Bone Resorption induced by The Absence of 
Estrogen 
Estrogen deficiency causes a global increment in IL-7 production, especially in 
thymus, spleen and bone marrow, in turn increasing the T cell pool. T cells produce 
elevated levels of proinflammatory cytokines including TNF-alpha, IL-1, and IL-6. 
These cytokines promote increased RANK L expression on osteoblasts and stromal 
cells, which further leads to osteoclast differentiation in the presence of M-CSF. 
(Adapted from Zhao R, 2012) 
(b) REGULATION OF BONE METABOLISM BY TGF- a & IFN-y 
Estrogen (E) exerts multifactorial control over bone remodeling. Most of the 
bone-sparing activity exerted by E occurs through modulation of bone cell 
life-span and decreased cytokine-driven osteoclastogenesis (Kousteni et al., 
2001; Riggs et al., 2002). Among the factors that up-regulate OC formation and 
lead to bone loss in estroprevic humans and rodents is tumor necrosis factor alpha 
(TNF-a) (Nanes MS., 2003). This E regulated cytokine promotes 
osteoclastogenesis by augmenting the production of RANKL 
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(Pfeilschifter et al, 2002), the non-redundant cytokine responsible for OC 
development (Hofbauer et al., 2000) and by increasing the responsiveness of 
maturing 0€s to this factor (Cenci et al., 2000; Lam et al, 2000; Zhang et al, 
2001). Besides, TNF stimulates the production of other cytokines knovra to be 
implicated in the pathogenesis of ovariectomy (ovx) induced bone loss, such as 
IL-l, IL-6, IL-7, and macrophage colony stimulated factor (M-CSF) 
(Pfeilschifter et al., 2002). ovx increases TNF levels in the bone marrow (BM) 
via an expansion of the pool of TNF-producing T cells (Cenci et al., 2000; 
Roggia et al., 2001) induced by a complex mechanism driven by interferon 
gamma (IFN-a) (Cenci et al., 2003). IFN- a augments antigen (Ag) presentation 
by enhancing MHC D expression on BM macrophages (BMMs), through 
induction of class D transactivator (CDTA) expression (Boss & Jensen, 2003). 
Up-regulation of Ag presentation results, in turn, in the increased T cell 
activation. Thus, up-regulation of IFN-a production induced by ovx leads to the 
increased T cell proliferation and life-span, a phenomenon that result in an 
increase in both the total number of T cells and the pool of TNF-producing 
T cells (Cenci et al, 2003). T cell-produced TNF plays key role in the ovx-
induced bone loss, as demonstrated by the failure of ovx to induce bone loss in 
T cell-deficient nude mice and by the ability to reconstitute with WT T cells, but 
not TNF-/- T cells, to restore a normal response to ovx (Cenci et al., 2000; 
Roggia etal., 2001). 
TGF- a has been reported to repress the production of IFN-y by directly targeting 
T cells and inhibiting their proliferation(Kehrl et al.,1986) and differentiation into 
effector cells (Gorelik & Flavell, 2002). Also, TGF-a is recognized for its ability 
to repress the production of and responsiveness to numerous cytokines relevant 
for bone homeostasis. For example, TGF-a signaling in BMMs decreases the 
responsiveness of the CDTA gene to IFN-a (Lee et al., 1997; Nandan and Reiner, 
1997) via a mechanism involving Smad 3 (Dong et al., 2001), whereas targeting 
of stromal cells and OBs by TGF-P blunts BM production of IL-7 (Tang et al., 
1997). Thus, TGF- a blocks T cell activation and T cell TNF production. Because 
the levels of TGF-a in bone and serum are increased by E and blunted by ovx 
(Gray et al., 1989; Finkelman et al, 1992; Bord et al, 2001), TGF-p may be a 
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pivotal upstream target of E in bone as is suggested by E failure to prevent bone 
loss in mice with a T cell-specific blockade of TGF-a signaling and complete in 
vivo prevention of ovx-induced bone loss by overexpression of TGF beta. 
However still, TGF-P and IFN- a have contradicting effects on bone metabolism. 
IFN-y and TGF-P have opposing effects on diverse cellular functions 
(Lake et al., 1994; Bauvois et al., 1992; Schmitt et al., 1994). IFN-y signals 
through the Janus kinase STAT pathway (Stark et al., 1998; Schindler & 
Darnell., 1995; Ihle JN., 1995) which is generally antagonistic to TGF-P 
signaling through SMADS-2 and -3 (Massague J., 1998; Heldin et al., 1997) in 
the regulation of hemopoietic and immune-cell function (Letteria & Roberts., 
1998; Ohta et al.,1987). TGF-P has been found to strongly promote 
TRAP-positive cell formation from mononuclear phagocyte precursors in 
response to TNF- a, whereas IFN-y primes these precursor cells for cytocidal 
macrophage activity (Ding et al., 1988; Russell et al., 1977; Weinberg et al., 
1978; Ruco & Meltzer., 1978) while inhibiting TRAP-positive cell formation. 
(c) REGULATION OF GLUTATHIONE / THIOREDOXIN AND 
GLUTATHIONE PEROXIDASE ACTIVITY BY ESTROGEN 
Evidence is accumulating that the beneficial effects of E on lipids, endothelial 
cells, and neurons emanate through improved defense against oxidative stress 
(Sack et al., 1994; Sudoh et al., 2001). The physiological levels of E are shown to 
maintain thiol antioxidants in rodent bone marrow as is evidenced by the a 
substantia] decrease in the level of glutathione and thioredoxin, the major tissue 
thiol antioxidants, and in the enzymes that regenerate their reduced forms in bone 
marrow of ovx-rats (Jenny et al., 2003). OCs, the bone resorbing cells, is 
identified as a target for the augmentation of oxidant-defense enzymes by 
estradiol thereby modulating ROS-sensitive pathways in OCs. Infact, OCs are a 
prime candidate for regulation of ROS since they express NADPH oxidase 
(Steinback et al, 1994), an enzyme capable of the cytokine-regulated 
generation of ROS during bone resorption (Garrett et al., 1990). Besides, the 
activity of OCs is dependent upon several intracellular signals that are sensitive 
to ROS, including NF-kB, JNK, P13K, and p38MAP kinase. ROS might also 
indirectly stimulate OCs by augmenting expression of resorptive cytokines such 
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as IL-1, IL-6 and TNF-a that have been strongly implicated in E-deficiency bone 
loss (Jilka et al, 1992; Kitazawa et al., 1994; Roggia et al., 2001). Moreover, 
ROS and TNF-a not only stimulate resorption but also suppress osteoblastic 
differentiation (Mody et al., 2001; Gilbert et al., 2002; Panagakos et al, 1996; 
Samoto et al., 2002). ROS may perturb osteoblastic fiinction by inactivating 
nitric oxide (NO), deficiency of which is known to impair bone formation in vivo 
(Armour etal., 2001). 
The expression of GPx, the major enzyme responsible for the intracellular 
degradation of H2O2, modulates the activity of OCs. H2O2 has been shown to 
directly stimulate OC formation and function (Bax BE et al., 1992; Lean JM. et 
al., 2003). Bone sparing activity of E has been linked to its ability to induce GPx 
expression in OCs (Lean et al., 2004). Overexpression of GPx in RAW cells has 
been shown to abrogate OC differentiation via a suppression of NF-eB signaling 
pathway which is ROS sensitive. Exposure of cells to H2O2 leads to the induction 
of expression of cytokines (IL-1, IL-6, TNF-a) implicated in E-deficiency bone 
loss (Kitazawa et al., 1994; Roggia et al., 2001). H2O2 might also cause bone loss 
by up-regulation or down-regulation of the expression by bone cells of RANKL 
or OPG, or through the induction of apoptosis in osteoblastic cells (Kousteni et 
al., 2002). 
REACTIVE OXYGEN SPECIES (ROS) 
Reactive oxygen species (ROS) are chemically reactive molecules containing oxygen 
and free radicals such as superoxide (O* ), hydrogen peroxide (H2O2), and the 
hydroxyl radical (OH) and are generated as natural by-products of normal oxygen 
metabolism. Cells have antioxidant systems, including endogenous enzymes and 
exogenous substances, that eliminate ROS in order to defend themselves against ROS 
damage. Increases in ROS production and/or decreases in antioxidant defense can 
result in significant damage to cell structures, culminating in a situation known 
as oxidative stress. Since oxidative stress is thought to be a pivotal cause of aging in 
mammals, a growing body of evidence in human studies suggests that cumulative 
oxidative damage may be responsible for age-associated bone fragility; however, no 
causative link has yet been proven definitively (Nojiri H, Saita Y et al., 2011). 
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PRESENT STUDY 
The present study employs a variety of biological effects of allicin are attributed both 
to its SH-modifying and antioxidant properties (Prasad, K et al., 1995; Ankri, S et ah, 
1997). L-cysteine of the antioxidant glutathione may also be a target of allicin (Ankri 
S and Mirelman D, 1999; Rabinkov A et al., 2000). Also, garlic has been reported to 
scavenge (O2, H2O2 and OH) in a concentration dependent manner (Chaverri JP et al., 
2006). Earlier studies involving allicin at higher concentrations have proven to be 
toxic (Ankri S et al., 1997). Thus, in the present study a lower non-toxic concentration 
of allicin (500 ng/ml) was used to control the increased TNF-a production due to ROS 
production, and in turn, a variety of bone markers in culture monocytes as well as to 
investigate the potential mechanism involved in downregulating TNF-a, which in turn 
may help in understanding the use of allicin in osteoporosis therapy. The structure of 
allicin is depicted below in Figure (h). Furthermore, the bioconversion pathway of 
garlic organosulpher compounds is depicted in Figure (i). 
Figure (h): Allicin, lUPAC Name: 2-Propene-l-sulfinothioic acid S-2-propenyl 
ester; Molecular Formula: C6H10OS2. (Adapted from wikipedia.org) 
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Figure (i): Bioconversion pathway of Garlic Organosulfur Compounds, 
(Adapted from lpi.oregonstate.edu) 
Epigallocatechin gallate (EGCG), also known as epigallocatechin 3-gallate, is 
the ester of epigallocateciiin and gallic acid, and is a type of cateciiin. EGCG is the 
most abundant catechin in tea and is a potent antioxidant that may have therapeutic 
applications in the treatment of many disorders (e.g. cancer). It is found in green tea, 
but not black tea; during black tea production, the catechins are converted to 
theaflavins and thearubigins (Lorenz M and Urban J, 2009). In a high temperature 
environment, an epunerization change is more likely to occur; however as exposure to 
boiling water for SOminutes leads to only a 12.4% reduction in the total amount of 
EGCG, the amoimt lost in a brief exposure is insignificant. In fact, even when special 
conditions were used to create temperatures well above that of boiling water, the 
amount lost increased only slightly (Wang R et al., 2008). The structure of EGCG is 
depicted below in Figure (j) 
Page 29 
Introduction 
EGCG J 
Figure (j): Chemical structure of EGCG (Adapted from ikerbill.hubpages.com) 
An expanding body of preclinical evidence suggests EGCG, the major catechin found 
in green tea (Camellia sinensis), has the potential to impact a variety of human 
diseases. Apparently, EGCG functions as a powerful antioxidant, preventing oxidative 
damage in healthy cells, but also as an antiangiogenic and antitumor agent and as a 
modulator of tumor cell response to chemotherapy. Much of the cancer 
chemopreventive properties of green tea are mediated by EGCG that induces 
apoptosis and promotes cell growth arrest by altering the expression of cell cycle 
regulatory proteins, activating killer caspases, and suppressing oncogenic 
transcription factors and pluripotency maintain factors. In vitro studies have 
demonstrated that EGCG blocks carcinogenesis by affecting a wide array of signal 
transduction pathways including JAK/STAT, MAPK, PI3K/AKT, Wnt and Notch. 
EGCG stimulates telomere fragmentation through inhibiting telomerase activity. 
Various clinical studies have revealed that treatment by EGCG inhibits tumor 
incidence and multiplicity in different organ sites such as liver, stomach, skin, lung, 
mammary gland and colon. Recent work demonstrated that EGCG reduced DNMTs, 
proteases, and DHFR activities, which would affect transcription of TSGs and protein 
synthesis. EGCG has great potential in cancer prevention because of its safety, low 
cost and bioavailability (Singh BN et al., 2011). Reports indicate that 
tT. • C - . ^ » ^ 
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(-)-Epigallocatechin-3-gallate suppresses osteoclast differentiation and ameliorates 
experimental arthritis in mice (Morinobu A et al., 2008). Thus, in the present study, 
EGCG has also been employed to probe its effect on human cells from osteoporosis 
patients. 
BACKGROUND 
(a) It's a well established fact that due to augmented generation of reactive oxygen 
species (ROS) in vivo due to a wide spectrum of reasons leads to the activation 
and up-regulation of bone markers like pro-inflammatory cytokine TNF-alpha 
and it's superfamily member Osteoprotegrin (OPG) as well as calcitonin at both 
the protein and gene levels. 
(b) This in turn results in augmentation in osteoclast differentiation, thereby 
resulting in bone loss and fractures. 
STRATERGY 
Thus, in view of the above, if generation of reactive oxygen species (ROS) in vivo is 
arrested by natural antioxidant freatment like allicin and EGCG, then levels of bone 
markers like TNF-alpha and it's superfamily member Osteoprotegerin (OPG) as well 
as calcitonin will be down-regulated, which in turn will result in suppressed osteoclast 
differentiation. This in turn would help bones to be healthy and less susceptible to 
fractures. 
Therefore, the present study focuses on Allicin, the main biologically active 
component of freshly crushed garlic, as well as EGCG from green tea, as a potential 
agent to counteract the ROS and pathological effects of increased TNF-a production 
in osteoporosis. Also, allicin and EGCG, as natural antioxidants, has been employed 
in the present study to regulate bone makers, and in turn, may help in the better 
understanding in the management of osteoporosis. 
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MATERIALS 
Recombinant human (rh) TNF-a, monoclonal anti-TNF-a antibody, soluble N-acetyl-
cysteine, H2O2, SN50 (an inhibitor of NF-KB) and its analogue SN50/M, agarose, 
bovine serum albumin, Coomassie Brilliant Blue G-250 and R-250, p-nitrophenyl 
phosphate, anti-human IgG alkaline phosphate conjugate, Tween-20, dithiothreiotol, 
phenylmethylsulphonyl fluoride, standard protein markers, sodium azide, ethidium 
bromide, chloroform, isoamyl alcohol, reduced glutathione and glutathione reductase 
and EGCG were from Sigma Chemical Company, U.S.A. SN50 is a hybrid peptide 
containing nuclear localization sequence of p50 subunit of NF-KB heterodimer and 
has been shown to completely inhibit the translocation of NF-KB in human cell lines 
atlOO^g/ml(Linetal., 1995). 
AUicin was obtained from LK.T Laboratories, Inc. U.S.A. Ficoll-Paque was from 
Pharmacia, Piscataway, NJ, U.S.A. Middlebrook 7H9 broth, Middlebrook ADC 
enrichment fluid, RPMI-1640 medium were from HiMedia, India. MTT cell viability 
assay kit and immunoassay kits for TNF-a were from R & D Systems, U.S.A. 
12-wells tissue culture plates were obtained from Techno Plastic Products (TPP), 
Switzerland. Polystyrene microtitre flat bottom ELISA plates having 96 wells (7 mm 
diameter) were from NUNC, Denmark. All other chemicals were of the highest 
analytical grade available. 
STUDY SUBJECTS 
Venous blood was obtained from healthy volunteers of both sexes (n=30) with no 
history of osteoporosis. Also, blood from patients with osteoporosis (n=50) was 
obtained from the patients attending J.N. Medical College Hospital of A.M.U. Serum 
was separated Jind stored at -20''C until required. 
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DETERMINATION OF PROTEIN CONCENTRATION 
Protein was estimated by the methods of Lowry et al. (1951) and Bradford (1976). 
(A) PROTEIN ESTIMATION BY THE LOWRY (FOLIN-CIOCALTEAU) 
METHOD 
Protein estimation by this method involves complexing of the protein's peptide bonds 
with Cu^ ^ under alkaline conditions (Lowry et al., 1951). The resultant Cu^ appears to 
catalyze the oxidation of tyrosine and tryptophan residues by reducing 
phosphomolybdotungstate anions in the Folin reagent (a mixture of sodium tungstate, 
molybdate and phosphate), added subsequently. This reaction develops a blue colour 
due to the formation of heteropolymolybdenum blue, which can be quantified by its 
absorbance at 660 nm. 
Reagents 
(i) Folin-Ciocalteau reagent 
The reagent was diluted 1:4 with distilled water before use. 
(ii) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as follows: 
(a) 2% sodium carbonate in 100 mM NaOH 
(b) 0.5% copper sulphate in 1% sodium potassium tartarate 
The working reagent was prepared fresh before use by mixing the two components in 
the ratio 50:1, respectively. 
Procedure 
To 1.0 ml of protein sample was added 5.0 ml of freshly prepared alkaline copper 
reagent. After thorough mixing, the reaction mixture was allowed to stand at room 
temperature for 10 minutes, followed by the addition of 1.0 ml of 1:4 times diluted 
Folin-Ciocalteau reagent. The contents were mixed immediately. The reaction was 
allowed to proceed for 30 minutes at room temperature and each tube was 
subsequently monitored at 660 nm. The protein content of the unknown sample was 
determined by using bovine serum albumin to construct a standard calibration curve. 
Page 33 
Material and Methods 
(B) PROTEIN ESTIMATION BY THE BRADFORD METHOD 
This method is based on strong binding of the dye Coomassie Brilliant Blue G-250, 
in acidic medium, to protein hydrophobically and at positively charged groups 
(Bradford, 1976). In the environment of these positively charged groups, protonation 
is suppressed and a blue color develops (Xniax-595 nm). 
Preparation of dye 
100 mg of Coomassie Brilliant Blue G-250 was dissolved in 50 ml of 95% ethanol 
and 100 ml of 85% (v/v) orthophosphoric acid was added. The resulting solution was 
diluted to a final volume of 1.0 litre and filtered through Whatman No. 1 filter paper 
to remove undissolved particles. 
Procedure 
To 1.0 ml of solution containing 10-100 i^g protein was added 5.0 ml of dye solution. 
The contents were mixed thoroughly by vortexing. The absorbance was read at 595 
imi after 5 minutes against a reagent blank. 
POLYACRYLAMIDE GEL ELECTROPHORESIS OF PROTEINS 
Polyacrylamide gel electrophoresis was performed under denaturing conditions as 
described by Laemmli (1970). 
REAGENTS 
(i) Acrylamide-bisacrylamide (30:0.8) 
A stock solution of 30% acrylamide containing 0.8% bisacrylamide was prepared 
by dissolving 30 gm of acrylamide and 0.8 gm of bisacrylamide in a total volume 
of 100 ml. The solution was stored at 4''C in an amber coloured bottle. 
(ii) Resolving gel buffer 
A stock solution was prepared by dissolving 36.3 gm Tris base in 48 ml of 1 N 
HCl. The contents were mixed, pH adjusted to 8.8 and the final volume brought 
to 100 ml with distilled water. 
(iii) Stacking gel buffer 
6.05 gm Tris was dissolved in 40 ml distilled water, pH adjusted to 6.8 with 1 
N HCl and the final volume adjusted to 100 ml with disfilled water. 
(iv) Electrode buffer 
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3.03 gm Tris, 14.4 gm glycine and 1.0 gm SDS were dissolved in distilled water, 
pH adjusted to 8.3 and the final volume made up to 1.0 litre with distilled water. 
(v) Sample buffer 
a) 6.0 gm of Tris was dissolved in 80 ml distilled water and pH adjusted to 6.8 
with phosphoric acid. The final volume was brought to 100 ml with distilled 
water. 
b) 1.0 mg of bromophenol blue and 12.5 ml of glycerol were added to 12.5 ml of 
the above solution. P-mercaptoethanol was added just before use. 
Recipe for 10-20% Gradient Gel 
Resolving Gel (total volume: 30 ml) 
Reagents 
Acrylamide-bisacrylamide (30:0.8) 
Resolving gel buffer 
10% SDS 
10% Ammonium persulphate 
TEMED 
10% 
5.0 ml 
3.8 ml 
150 l^l 
50^1 
10|il 
20% 
10 ml 
3.8 ml 
150^1 
50^1 
10 ^ il 
The fmal volume was raised to 15 ml each with distilled water. 
2.5% Stacking Gel (total volume: 10 ml) 
Acrylamide-bisacrylamide (30:0.8) 
Stacking gel buffer 
10% SDS 
10% Ammonium persulphate 
TEMED 
0.8 ml 
2.5 ml 
100 ^ il 
75^1 
25\i\ 
The fmal volume was raised to 10 ml with distilled water. 
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Recipe for 7.5% SDS-PAGE (total volume: 10 ml) 
Acrylamide-bisacrylamide (30:0.8) 
Resolving gel buffer 
10%SDS 
10% Ammonium persulphate 
TEMED 
2.5 ml 
2.5 ml 
100 til 
50^1 
10 i^l 
The final volume was raised to 10 ml with distilled water. 
PROCEDURE 
The glass plates (18 cm x 16 cm) were soaked in chromic acid and thoroughly washed 
with tap water followed by a final rinse with distilled water and ethanol. The plates 
were dried and sealed with 1% agarose and 1.5 mm thick spacers. The reagents were 
mixed and poured between the glass plates. The resolving gel was allowed to 
polymerize at room temperature, following which, the stacking gel was layered on 
top. A well-forming comb was inserted immediately and the gel was left to 
polymerize at room temperature, hi case of gradient gels, a gradient of resolving gel 
was formed with the help of a gradient former (Bio-Rad, model 385). After ensuring 
complete polymerization, the protem samples (25-100 ng) m one-fourth volume of 
sample bufter were electrophoresed at 80 volts at room temperature. The gels were 
stained using 0.25% Coomassie BriUiant Blue R-250 or with silver stain reagent. 
SILVER STAINING 
Silver staining was done by the method of Merril et al. (Merril et al., 1983). Briefly, 
the gel was incubated in 40% methanol and 12% acetic acid for 45 minutes followed 
by incubation in 50% ethanol for 30 minutes. Next the gel was treated with 
0.02% hypo (sodium thiosulphate) for 1 minute. After washing with distilled water, 
the gel was placed in 0.2%) silver nitrate (with 0.05% v/v formaldehyde), washed 
again with distilled water, and transferred to a 6% solution of sodium carbonate 
(with 0.05% v/v formaldehyde). After color development, the gel was washed with 
distilled water and the reaction was arrested by treating the gel with 3%) v/v acetic 
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acid and 5% v/v methanol. All the reagents used in this procedure were freshly 
prepared. 
AGAROSE GEL ELECTROPHORESIS 
Agarose gel was prepared by bringing 2% agarose to molten state in electrophoresis 
buffer (0.04 M Tris acetate, pH 8.0 containing 0.002 M EDTA). Molten agarose was 
poured on the gel tray and allowed to soUdify for 1 hour at room temperature. The 
nucleic acid samples in one-tenth volume of stop-mix (30% ficoll, 0.025% xylene 
cyanole FF and 500 mM EDTA in lOX TAB buffer) were electropheresed for 2-4 
hours at 30 mA in the same buffer. The gel was stained with ethidium bromide 
(0.5 ng/ml). 
PREPARATION OF RPMI-1640 MEDIUM 
Dehydrated RPMI-1640 medium of one unit vial (16.3 gm) was suspended in 950 ml 
of tissue culture-grade water at room temperature with constant, gentle stirring until 
the medium was completely dissolved. The container was rinsed with tissue culture 
grade water to remove all traces of powder and added to the above solution. 3.7 gm 
sodium bicarbonate was added to the medium and stirred until dissolved. The final 
volume was brought to 1000 ml with tissue culture grade water. The medium was 
sterilized immediately by filtering through a sterile membrane filter with a porosity of 
0.22 micron using positive pressure rather than vacuum to minimize the loss of carbon 
dioxide, and stored at 4°C till use. 
PREPARATION OF PBMC 
Step 1 In order to isolate peripheral blood mononuclear cells (PBMCs), 60 ml of 
blood was drawn fi"om a healthy volunteer and patients into 60 cm syringes 
containing 3.8 units heparin/ml. The heparinized blood, in 15 ml aliquots, 
was transferred to sterile 50 mi polypropylene centrifuge tubes and diluted 
1:1 with sterile 10 mM, PBS, pH 7.4 at room temperature, followed by 
gentle mixing by inverting the tube a few times. 
Step 2 Diluted blood was underlayered with 15 ml of Ficoll-Paque at room 
temperature using an 18 gauge spinal needle. Care was taken to prevent 
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mixing of the layers. The gradient was centrifiiged at 1800 rpm for 30 
minutes at room temperature with the centrifuge brake turned off. 
Step 3 Using a sterile pipette, the upper clear layer containing plasma was 
removed. The PBMCs appeared as a dense white band (huffy layer) above 
the red blood cells and granulocytes layer. This was removed with another 
sterile pipette. The banded cells were combined in 10 ml aliquots. 
Step 4 Ten milliliters of banded PBMCs were diluted with 25 ml of PBS in sterile 
50 ml polypropylene centrifuge tubes and centrifiiged at 1100 rpm for 
12 minutes at room temperature to remove platelets, which remain in the 
supernatant. The PBMC pellets were combined to four tubes, diluted in 
30 ml PBS and centrifiiged at 1100 rpm for 10 minutes at room 
temperature. This wash was repeated. 
Step 5 The pellets were then combined and resuspended in 30 ml complete 
medium (CM) (RPMI-1640 medium containing 2 M L-glutamine, 25 mM 
HEPES, and no antibiotics). An aliquot was diluted 20-fold and counted 
using a hemocytometer under a light microscope using lOx ocular and 
40x objective. 
PREPARATION OF AUTOLOGOUS SERUM FOR MONOCYTE 
CULTURE 
From the samic donor, 30 ml of blood was drawn without anticoagulant and 
transferred to serum separator tubes. The blood was allowed to clot for at least 
30 minutes, then centrifiiged at 3000 rpm for 15 minutes at room temperature and the 
serum filtered through a sterile 0.22 \im filter unit. Autologous serum can be stored 
for a year or longer at -20°C. 
ASSAY FOR CELLULAR GLUTATHIONE (GSH) CONTENT 
Glutathione was measured according to the method described by Hasan (Hasan et al 
2007). Adherent monocytes obtained from PBMCs of healthy and osteoporosis 
patients, treated with either Allicin/ EGCG, were collected (600 g, 7 min, 4°C) and 
washed with PBS. After protein precipitation with 5% metaphosphoric acid 
(0.2-0.3 ml/5 X10*' cells) by centrifiigation (10,000g, for 30 min), the supernatant was 
used for GSH quantitation, and the pellet, dissolved in 0.2-0.3 ml of 0.5 M NaOH, 
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was used for protein determination. Samples (40 \i\) were neutralized with 
2 M triethanolamine (10 \i\) in a 96-well plate. The reaction was started by adding 
200 |xl per well of 0.4 U/ml Glutathione reductase enzyme in 143 mM phosphate 
buffer pH 7.5 containing 0.3 mM reduced nicotinamide adenine dinucleotide 
phosphate, 0.6 mM DTNB and 6.25 mM EDTA. The initial rate of 
5-thio-2-nitrobenzoic acid formation was monitored. Similarly, effect of pretreatment 
of BSO (100 pM, 24 h) on the GSH content of monocytes from PBMCs, treated with 
or without AUicin/EGCG, was also determined. 
ASSAY FOR GLUTATHIONE PEROXIDASE (GPX) ACTIVITY 
The activity of glutathione peroxidase (GPx) was measured as described elsewhere 
(Mohandas et al., 1984; Mates et al., 1999). The oxidized glutathione (GSSG) 
produced during GPx reaction was immediately reduced by NADPH and glutathione 
reductase. Therefore, the rate of NADPH consumption was regarded as the rate of 
GSSG formation during the GPx reaction. Monocytes from healthy donors and 
patients with osteoporosis were co-cultured for 24 hours with or without 
10 mM NAC, 100 ^g/ml SN50, 100 ng/ml SN50/M and 0-500 ng/ml allicin. 
Thereafter, cells were gently scraped with lysis buffer containing protease inhibitors 
(50 mM Tris/HCl, pH 7.4; 1 mM EDTA; 500 mM PMSF). Protein concentrations of 
supematants were determined by the method of Bradford with BSA as the standard, 
and were subjected to GPx activity determination. The reaction mixture (1.0 ml) 
containing 50 mM potassium phosphate (pH 7.0), 1 mM sodium azide, 2 mM GSH, 
0.2 mM NADPH, 1 unit/ml glutathione reductase, 1.5 mM cumene hydroperoxide, 
and 20-100 |xl of samples were incubated at 25°C for 5 minutes. The reaction was 
initiated by the addition of cumene hydroperoxide. The kinetic change was 
specfrophotometrically recorded at 340 nm (37°C) for 3 minutes. GPx activity was 
calculated after subfraction of the blank value, as |imol of NADPH 
oxidized/minute/mg protein (U/mg protein). 
DETERMINATION OF MALONDIALDEHYDE (MDA) LEVELS 
Determination of MDA levels were carried out as described by Kaur et al. (Kaur K et 
al, 2012). The lipid peroxide levels in treated/untreated monocyte cultures in healthy 
subjects as well as patients were measured by precipitating the lipoproteins with 
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trichloroacetic acid and boiling them with thiobarbituric acid, which reacted with 
malondialdehyde to form a pink colour, as per the 'Kei satoh' method 
(Satoh K, 1978). The resulting chromogen was extracted with n-butyl alcohol and the 
absorbance of the organic phase was determined at the wavelength of 530nm. The 
determined values were expressed in terms of malondialdehyde in nmol/ml. 
CELL CULTURE 
PBMCs (5x10^ cells/well) were added in 12-wells tissue culture plates in complete 
RPMl-1640 medium, and were subsequently incubated at 37°C, 5% CO2 for 
1-2 hours for adherence. Thereafter, non-adherent cells were removed by washing the 
plates extensively 4 tunes with RPMI-1640 medium. The adherent monocytes were 
cultured in RPMI-1640 supplemented with 2% autologous serum, followed by 
overnight resting at 37°C, 5% CO2. This population of adherent cells is up to 
95% monocytes, as observed by cytostaining and is 99% viable (Toossi et al., 1996). 
Prior to treatment with supplements/compounds, the plates were washed twice with 
RPMI-1640 medium. 
TREATMENT WITH ALLICIN/EGCG AND MONOCYTES 
VIABILITY ASSAY 
The effect of allicin (0-500 ng/ml) and EGCG (0-20 ^g/ml) on the viability of 
monocytes was assessed by using MTT Cell Viability Assay Kit (R&D Systems) 
according to the manufacture's instructions provided. 
REAGENTS SUPPLIED IN THE KIT 
Component 
MTT reagent 
Detergent reagent 
Quantity 
25 ml 
250 ml 
Storage conditions 
2-8°C 
18-24°C 
Assay procedure 
Adherent monocytes from healthy donors and patients with osteoporosis were gently 
scraped with RPMI-1640 medium. After this, monocytes (3 x 10"* cells/well 
in 100 |j.l) were added in 96-well tissue culture plates. Cells were incubated in 
RPMI-1640 M/ith 2% autologous serum containing allicin (50, 100, 250, and 
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500 ng/ml) and EGCG (0, 5, 10, 15 and 20 |ig/ml) respectively for 24 hours at 37°C, 
5% CO2. After 24 hours, 10 ^1 of MTT reagent (3-[4, 5-dimethylthiazol-2-yl]-2, 5-
diphenyltetrazolium bromide) was added to each well and incubation was continued 
for an additional two hours. When a purple precipitate was clearly visible under the 
microscope, 100 \i\ of detergent reagent was added to all wells, including control wells 
and incubated for two hours in the dark at 20°C. After incubation, the precipitate was 
solubilized and the absorbance of the resulting solution was measured at 570 run using 
a microplate reader. Control cells were treated exactly the same except that no 
allicin / EGCG was added to the wells. The percentage of viable cells was calculated 
by the formula as described by Islam et al. (Islam et al., 2000) and the results are 
expressed as "Viable cells (% of control cells)". 
Absorbance value of control cells 
Viable monocytes (% of control cells) = x 100 
Absorbance value of treated cells 
TRYPAN BLUE EXCLUSION ASSAY FOR MONOCYTES 
VIABILITY 
Adherent monocytes were gently scraped with RPMI-1640 medium. Trypan blue 
suspension (1.6 mg/ml in saline solution) was added to the monocytes at a final 
concentration of 0.8 mg/ml. The cells were kept at 37°C for 7 minutes in a 
CO2 chamber (5%), mounted on a hemocytometer and then observed under light 
microscope. The cells taking up Trypan blue (dead cells), and cells excluding the dye 
(viable cells) were counted. Percentage of viable cells was calculated by the following 
formula: 
Total viable cells (unstained) 
Percent Cell viability = x 100 
Total cells (stained plus unstained) 
CULTURE CONDITIONS FOR HUMAN OSTEOCLASTOGENESIS 
ASSAYS 
Whole population of freshly isolated PBMNC was plated in 96-well plates at 
6 X 10^  cells per well in 0.2 ml of medium (a-MEM, Gibco, pH 7.4, containing 10% 
PCS from Amimed, batch #803485). Medium was also supplemented with the 
followmg cytokines, growth factors and hormones: 25 ng/ml human M-CSF (R&D 
Systems, Abingdon, UK), 50 ng/ml human RANKL (Insight Biotechnology, 
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Wembley, UK)., 5 ng/ml human TGF-pi (R&D Systems, Abingdon, UK), and 
1 |xM dexamethasone (Sigma, Buchs, Switzerland). The cells were re-fed twice 
weekly by demi-depletion (half of the medium withdrawn and replaced with the fresh 
medium). The culture duration was 17 days followed by TRAP staining. 
EFFECT OF ALLICIN FROM GARLIC AND EPIGALLOCATECHIN 
GALLATE (EGCG)- A GREEN TEA POLYPHENOL AND A 
NATURAL ANTIOXIDANT, ON GENERATION OF OSTEOCLASTS 
FROM PBMCS 
To investigate the effect of natural antioxidants on osteoclast generation from 
PBMCs, varying doses of allicin from garlic (0-500 ng/ml) and EGCG from green tea 
(0-25 ng/ml) were added to the PBMC cultures seeded at a cell density of 
2x10^ cells/cm^ in a 96-well plate in a osteoclastogenic medium as described above 
and incubated for 24 h (1 day), 72 hours (3 days) and 120 hours (5 days) at 37°C in a 
humidified atmosphere of 5% C02. Thereafter, the cells were analysed wdth TRAP 
staining. 
TRAP STAINING: QUANTIFICATION OF TRAP-POSITIVE 
MULTINUCLEATED CELL 
TRAP staining of adherent cultures was done with a kit from Sigma (Buchs, 
Switzerland) exactly according to manufacturer's instruction. The stained cells 
developed red color of different intensity. 
The numbers of TRAP-positive multinucleated cells were determined using the 
1 X l-ram grid placed in the ocular of the microscope. For TRAP assay, Zeiss 
Axiovert 100 microscope (Zeiss, Oberkochen, Germany) was used. The number of 
TRAP-positive multinucleated cells (>2 nuclei per cell) was measured at 
predetermined sites of the area of 1 x 1 mm. Five sites were measured in a well of a 
96-well plate, and a mean value was calculated. Four wells were measured in total per 
one condition and these results were expressed as mean ± SEM. Typical values for the 
number of TRj\P-positive muhinucleated cells in confrols were about 400-600 cells 
per well (96-well plate). 
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TRAP 5b ACTIVITY ASSAY 
Osteoclast differentiation was evaluated by the measurement of TRAPSb 
activity using naphthol-ASBI phosphate (N-ASBI-P, Sigma) as a substrate according 
to a slightly modified protocol of Heinemann C et al. (Heinemann C et al., 2011). Cell 
lysates were added to the TRAP 5b reaction buffer consisting of 2.5 mM N-ASBI-P in 
100 mM sodium acetate (Sigma) buffer containing 50 mM Na-tartrate (Sigma), 
2% NP-40 (Sigma) and 1% ethylene glycol monomethyl ether (EGME, Sigma) 
adjusted to pH 6.1 and the mixtures were incubated a t 37 °C for 1 h. The 
enzymatic reaction was stopped by adding 0.1 M NaOH and fluorescence was 
measured at an excitation wavelength of 405 imi and emission wavelength of 535 rmi. 
The relative fluorescence units were correlated to a TRAP 5b standard (Heinemarm, 
C.etal.,2011). 
ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) 
Antibodies were detected and quantified by ELISA using polystyrene flat bottom 
microtiter plates as solid phase (Alam and Ali, 1992, Islam and Ali, 1998). The 
method described by Islam and Ali, 1998 was followed for the assay. 
BUFFERS AND REAGENTS 
(i) Tris buffered saline (TBS) 
10 mM Tris, 150 mM NaCl, pH 7.4 
(ii) Tris buffered saline Tween-20 (TBS-T) 
20 mM Tris, 144 mM NaCl, 2.68 mM KCl and 1.0 ml/litre Tween-20, pH 7.4 
(iii) Bicarbonate bufTer 
15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 9.6 
(iv) Substrate buffer (for anti-human IgG alkaline phosphate conjugate) 
15 mM sodium carbonate, 35 mM sodium bicarbonate and 2 mM magnesium 
chloride, pH 9.6. 
Substrate: 0.5 mg/ml of p-nitrophenyl phosphate (p-NPP) 
Page 43 
Material and Methods 
1. DIRECT BINDING ELISA 
Polystyrene microtiter plates were incubated with 100 1^ of protein antigen 
(30 |ig/ml in carbonate/bicarbonate buffer, pH 9.6) for two hours at room 
temperature followed by overnight incubation at 4°C. The plates were washed 
thrice with TBS-T and unoccupied sites blocked by 150 |il of BSA (1.5% in TBS, 
pH 7.4) for 4-6 hours at room temperature. Serially diluted sera in TBS were 
added to lantigen-coated as well as control (antigen uncoated) wells. The 
antigen-antibody interaction was allowed to proceed for two hours at room 
temperature followed by overnight incubation at 4°C and subsequently the plates 
were washed four times with TBS-T in order to remove the unbound antibodies. 
Bound antibodies were assayed by means of appropriate anti-immunoglobulin 
alkaline phosphatase conjugate using p-nitrophenyl phosphate as substrate. The 
reaction was stopped with 3.0 N NaOH and the absorbance of each well was 
monitored at 405 nm on an ELISA microplate reader. Each sample was coated in 
duplicate and the results were expressed as a mean of Atest - Acontroi-
For nucleic acid antigen, the plates were coated with 100 i^l of calf thymus DNA 
at a concentration of 2.5 |ig/ml in TBS, pH 7.4 and incubated for two hours at 
room temperature followed by overnight incubation at 4°C. The rest of the steps 
were same as described above. 
2. INHIBITION ELISA: 
The antigen binding specificity of antibody was determined by inhibition 
experiments (Hasan et al., 1991). Varying concentration of inhibitors 
(0-20 ^g/ml) were mixed with a constant amount of antiserum or IgG. The 
mixture was incubated for two hours at 37°C followed by overnight incubation at 
4°C. The resulting immune complex was employed in the immunoassay instead 
of serum. The rest of the steps were as in direct binding ELISA. The results were 
expressed as percent inhibition. 
Percent inhibition = (1 - Ai„hibited/Auninhibited) x 100 
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TNF-a IMMUNOASSAY 
The concentration of TNF-a in various culture supematants as well as in serum of 
osteoporosis patients was determined by use of a commercial ELISA Kit ( R & D 
Systems). This assay employed the quantitative sandwich enzyme immunoassay 
technique. A monoclonal antibody specific for TNF-a was available pre-coated onto a 
microplate. Standards and samples were pipetted into the wells and any soluble 
TNF-a present was bound by the immobilized antibody. After washing away any 
unbound substances, an enzyme-linked polyclonal antibody specific for TNF- a was 
added to the wells. Following a wash to remove any unbound antibody-enzyme 
reagent, a substrate solution was added to the wells and colour developed in 
proportion to the amount of TNF-a bound in the initial step. The colour development 
was stopped and the intensity of the colour was measured. 
REAGENTS SUPPLIED IN THE KIT 
(i) TNF-o microplate 
96 well polystyrene microplate (12 strips of 8 wells) coated with a mouse 
monoclonal antibody against TNF-a. 
(ii) TNF-a conjugate 
21 ml of polyclonal antibody against TNF-a conjugated to horseradish 
peroxidase, with preservatives. 
(iii) TNF-a standard 
10 ng of recombinant human TNF-a in a buffered protein base with 
preservatives, lyophilized. 
(iv) Assay diiluent RDIF 
6 ml of a buffered protein base with preservatives. It contained a precipitate and 
was mixed well before and during use. 
(v) Calibrator diluent RD6-35 
21 ml of animal serum with preservatives. 
(vi) Wash buffer concentrate 
21 ml of a 25-fold concentrated solution of buffered surfactant with 
preservatives. 
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(vii) Colour reagent A 
12.5 ml of stabilized hydrogen peroxide. 
(viii) Colour reagent B 
12.5 ml of stabilized chromogen (tetramethylbenzidine). 
(ix) Stop solution 
6 ml of 2 N sulphuric acid. 
(x) Plate covers 
4 adhesive strips. 
WORKING REAGENTS 
(i) Wash buffer 
20 ml of wash buffer concentrate was diluted into deionized or distilled water to 
prepare 500 ml of wash buffer. 
(ii) Diluted calibrator diluent RD6-35 
20 ml of calibrator diluent RD6-35 was mixed with 80 ml of deionized or 
distilled water to yield 100 ml of diluted calibrator diluent RD6-35. 
(iii) Substrate solution 
Colour reagents A and B were mixed together in equal volumes within 15 
minutes of use to form substrate solution. It was protected from light. 
(iv) TNF-a standard 
TNF-a standard was reconstituted with 1.0 ml of distilled water. This 
reconstitution produced a stock solution of 10,000 pg/ml. The standard was 
allowed to sit for a minimum of 15 minutes with gentle agitation prior to making 
dilutions. 
ASSAY PROCEDURE 
50 jil of assay diluent RDIF was added to each well of 96 well polystyrene microplate 
coated with a mouse monoclonal antibody against TNF-a. Thereafter, 200 p.1 of 
standards, samples, or control per well was added, covered with the adhesive strip 
provided and incubated for 2 hours at room temperature. The plate was washed four 
times by filling each well with wash buffer using a squirt bottle. After washing, 
200 1^ of TNF-a conjugate was added to each well, covered with a new adhesive strip 
and incubated for 1 hour for cell culture supematants and 2 hours for serum samples 
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at room temperature. After four washings with wash buffer, 200 ^1 of substrate 
solution was added to each well and incubated for 20 minutes at room temperature in 
the dark, a blue colour appeared. Thereafter, 50 {xl of stop solution was added to each 
well to stop the reaction. Then the absorbance of each well was determined within 
30 minutes, using a microplate reader set to 450 nm. The cut off or lower limit of 
sensitivity was 4.4 pg/ml. 
INTERLEUKIN-lp (IL-ip) IMMUNOASSAYS 
The concentration of IL-ip in monocytic culture supemates were determined by 
Quantikine Human IL-ip Immunoassay Kits (R&D Systems, Inc., Mirmeapolis, MN, 
USA) according to manufacturer's instruction. This assay employs the quantitative 
sandwich enzyme immunoassay technique. A monoclonal antibody specific for IL-ip 
has been pre-coated onto a microplate. Standards and culture supemates are pipetted 
into the wells and any IL-ip present is bound by the immobilized antibody. After 
washing away any unbound substances, an enzyme-linked polyclonal antibody 
specific for IL-1|3 is added to the wells. Following a wash to remove any unbound 
antibody-enzyme reagent, a substrate solution is added to the wells and color develops 
in proportion to the amount of IL-ip bound in the initial step. The color development 
is stopped and the intensity of the color is measured. 
RNA EXTRACTION 
After lysis of monocytes in 0.5 ml TRIZOL Reagent, 200 i^l of chloroform was added 
to each sample, followed by vortexing for 2 minutes, and centrifiigation at 3000 rpm 
for 5 minutes. Samples were then transferred to fresh eppendorf tubes and centrifiiged 
at 14,000 rpm for 15 minutes at 4°C. The aqueous layer was harvested and transferred 
to a fresh tube. The aqueous layer obtained was mixed with 500 |il of chloroform-
isoamyl alcohol (24:1) and vortexed. RNA was precipitated using 50 |il of 
1 M sodium acetate and 475 nl of isopropanol at -20°C for 3 hours in the presence of 
glycogen. This was followed by centrifiigation at 14,000 rpm and the pellet obtained 
was washed two times with 75% ethanol, and resuspended in 87 1^ DEPC-water. 
DNAase 1 digestion (10 ^I of lOX DNAse 1 buffer in 0.5 M Tris pH 7.5, 
0.1 M MgCh, 1 mM DTT; and 50 ^ ig/ml BSA, 2.0 nl RNAase inhibitor; lOU RNAase 
free DNAase 1) was employed to remove DNA. The reaction was stopped by the 
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addition of 700 \i\ of 0.5 M NH4OAC and the RNA was re-extracted using 500 \i\ of 
acid phenol-chloroform (1:1). The aqueous layer was harvested, extracted again with 
chloroform-isoamyl alcohol and precipitated. 
REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION 
(RT-PCR) 
The DNAase-treated RNA was subjected to reverse transcription using oligo(dT) 
primers with Superscript II reverse transcriptase (Invitrogen, Life Technologies, 
USA) according to the manufacturer's instructions. RNA (2 fig) was transcribed into 
cDNA in a 20 \x\ reaction volume containing 50 mM Tris-HCl, pH 8.3, 75 mM KCl, 
3 mM MgCb, 10 mM DTT, 0.5 mM of each deoxynucleotide triphosphate, 25 |ag/ml 
oligo(dT)i2-i8 primers and 10 U/p,l of Superscript II reverse transcriptase, at 42°C for 
50 minutes. The reaction was then stopped by heating at 70°C for 15 minutes 
followed by rapid chilling on ice. 
PCR 
The primers used in the PCR are listed in Table 1. cDNA for P-actin was amplified 
with various primer sets supplied by (Stratagene, La Jolla, CA, USA). For PCR, 2.0 1^ 
of each cDNA sample was used as template in the PCR amplification. The reactions 
were carried out in a 50 1^ reaction volume containing 20 mM Tris-HCl, pH 8.4, 
50 mM KCl, 1.5 mM MgCb, 0.2 mM of each of the four dNTPs, 2U of Taq DNA 
polymerase (Invitrogen) and 0.2 \iM of each forward and reverse primers. After initial 
denaturation for 2 minutes at 95°C, 35 cycles at 95°C for 15 seconds, 60°C for 45 
seconds were performed, followed by 72°C for 1 minute. The reaction products were 
visualized by electrophoresis in 2% agarose after staining with 0.5 |ig/ml ethidium 
bromide. 
HUMAN PRIMER SEQUENCES FOR OSTEOCLAST MARKERS. 
18S rRNA: 
Forward: 5'-ACGGGGAATCAGGGTTCGA-3', 
Reverse: 5'-CTCGAAAGAGTCCTGTATT-3' 
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TNF-a 
TNF-a primer RT: GGTTTCTACAACA 
TNF-a primer R: GTTCGAGAAGATGATCTGACTGCC 
TNF-a primer F: AGGCGGTGCTTGTTCCTCA 
OPG 
OPG primer R: 5'-GGGGACCACAATGAACAAGTTG-3', 
OPG primer F: 5'-AGCTTGCACCACTCCAAATCC-3', 
QUANTITATIVE REAL-TIME RT-PCR 
Real-time quantitative reverse transcriptase PCR (RT-PCR) provides a sensitive, 
reproducible, and accurate method for determining mRNA levels in tissues or cells. 
The method is based on the detection of a fluorescent signal produced and monitored 
during the amplification process, without the need for post-PCR processing (Heid et 
al., 1996). 
Two important findings led to the discovery of real-time PCR. Fu-st, the Taq 
polymerase has a 5-3' exonuclease activity (Holland et al., 1991), apart fi"om its 
polymerase activity. Second, dual-labelled fluorogenic oligonucleotide probes have 
been created which emit a fluorescent signal only upon cleavage, based on the 
principle of fluorescence resonance energy transfer (CarduUo et al., 1988). In the 
TaqMan assay (Applied Biosystems, Foster City, CA, USA), these two principles are 
combined. In this system a probe, the so-called TaqMan probe, is designed to anneal 
to the target sequence between the classical forward and reverse primers. The probe is 
dually labelled, with a reporter fluorochrome (eg., 5-carbofluorescein, or FAM) at one 
end and a quencher dye (eg., N,N,N',N'-tetramethyl-6-carborhodamine, or TAMRA) 
at the other end. In the intact probe, the fluorescence emission of the reporter dye will 
be absorbed by the quencher dye. The probe will be degraded during the 
extension phase by the 5-3' exonuclease activity of the Taq polymerase, separating 
the reporter and quencher, thus resulting in an increase in reporter fluorescence 
emission. The amount of fluorescence released is directly proportional to the amount 
of product generated in each PCR cycle and thus can be applied as a quantitative 
measure of PCR product formation. 
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PROCEDURE 
Internal fluorescent hybridization probes were used in ABI Prism 7700 Detection 
System (ABI/PerkinElmer (PE) Biosystems, Foster City, CA, USA), which allows the 
sensitive and specific quantification of individual host (Hartel et al , 1999), by 
quantitative real-time RT-PCR. TaqMan^"^ PCR primers and probes as well as 
target-specific RT primer for each assay were designed as described elsewhere 
(Islam et al, 2004). The primer and probe sequences used have been previously 
reported (Islam et al., 2004). All probes were dually labeled with FAM at the 5' end 
and TAMRA at the 3' end. The proximity of the dye (FAM) and the quencher 
(TAMRA) on the intact probe prevents detection of any fluorescence. However, 
degradation of the probe during the course of PCR allows the release and detection of 
FAM (Holland et al., 1991). The PCRs for all amplifications were similar: 5 (il of 
each cDNA, 20 p,l of Taqman Universal PCR Master Mix (PE Biosystems), which 
contains optimal amounts of AmpliTaq Gold DNA polymerase (which protects 
against amplicon carryover) and of dNTPs, and optimal amounts of probe and primers 
calibrated to allow measurement of the targets. First, cDNA was synthesized in the 
presence of 0.5 |il of murine leukemia virus enzyme (Invitrogen, USA)/reaction and 
10 .^M each RT primer, dNTPs, and other substrate. Conditions for PCR were similar 
for all products (1 cycle of 2 minutes at SO^ C and 1 cycle of 10 minutes at 95''C and 
then 40 cycles of 15 seconds at 95°C and 1 minute at 60°C). The cycle threshold for 
each sample was compared with the cycle threshold values of knovra amoimts of a 
standard DNA constructed for each target and amplified simultaneously. To assure 
lack of DNA contamination in the RNA samples, in some experiments, a duplicate 
tube of sample with no RT enzyme was included as control. DNA contamination 
remained negligible. In each sample, host 18S ribosomal RNA was used as the internal 
control. Expression of TNF-a mRNA was corrected to internal control (host 18S rRNA) 
in the same sample and was expressed as copies of TNF-a in 10 copies of R18 
(equivalent to 1 x 10^  monocytes). 
STATISTICAL ANALYSIS 
Results were analyzed by paired t-test and the data expressed as mean ± SEM of six 
experiments unless otherwise specified. P<0.05 was considered statistically 
significant. 
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Results 
The data of the present study is depicted under four sections as under: 
(A) Oxidative Stress Study in Serum and Monocyte Cultures 
(B) Immunological study by ELISA 
(C) Bone Marker Study by Quantitative 'Real time RT-PCR 
(D) Osteoclast and bone marker study by TRAP and ELISA 
In all the sections except section one as mentioned above, we employed allicin-a 
natural antioxidant from garlic as well as EGCG- a green tea polyphenol, to 
investigate its regulatory effect on vast parameters as discussed in the results depicted 
below. 
SECTION (A) OXIDATIVE STRESS STUDY IN SERUM AND 
MONOCYTE CULTURES 
(1) GPx activity in serum of osteoporotic patients 
Since high oxidative stress is associated with osteoporosis, thus, the anti-oxidant 
state of osteoporosis patients was assessed by determining the GPx activity in 
their sera. When compared to healthy subjects, the GPx activity in serum of 
patients with osteoporosis was appreciably reduced by around 2.2-fold. This is 
evident from data where GPx activity in sera of osteoporosis patients (n=30) and 
healthy controls (n=30) was recorded as 38.94 U/ mg protein and 88.12 U/ mg 
protein respectively (Figure 1). All values represent mean ± SE of ten 
experiments, p<0.001. 
(2) GPx activity in culture supematants of monocytes 
Adherent monocytes obtained from PBMCs of healthy controls as well as 
patients with osteoporosis were cultured for 24 hours as described in methods. 
Thereafter, supematants were analyzed for GPx activity, where patient's 
samples exhibited an appreciably suppressed GPx activity (23.25 U/ mg protein) 
when compared to samples of healthy subjects (69.76 U/ mg protein) (Figure 2). 
Thus, from the said data, it seems that antioxidant defense system is 
compromised by around 2.8-fold in patients with osteoporosis. All values are 
mean ± SE often experiments; p<0.001. 
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FIGURE 1: GPx activity in serum of osteoporosis patients and healthy controls. 
Data represent mean ± S.E.M. of ten independent experiments. p<0.001 was 
considered significant. 
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FIGURE 2: GPx activity in culture supematants of monocytes of osteoporosis 
patients and healthy controls. Data represent mean ± S.E.M. of ten independent 
experiments. p<0.001 was considered significant. 
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(3) Determination of intramonocyte glutathione (GSH) levels 
As a matter of fact, glutathione (GSH) being a major tissue thiol antioxidant, an 
attempt was made to evaluate the intramonocyte levels in 24 hour monocyte 
cultures of osteoporosis patients as well as in healthy individuals. As depicted in 
Figure 3, the magnitude of intramonocyte GSH were significantly suppressed in 
samples of osteoporosis patients (144.32 pg/ml) in comparison to healthy 
controls (256.65 pg/ml). The data indicates that antioxidant defense gets 
suppressed/reduced in osteoporosis patients in comparison to non-osteoporosis 
healthy subjects. All values are mean ± SE often experiments; p<0.001. 
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FIGURE 3: Intramonocyte Glutathione (GSH) levels in healthy controls and 
osteoporosis patients. Data represent mean ± S.E.M. often independent experiments. 
p<0.001 was considered significant 
Page 55 
Results 
(4) Dose response effect of allicin from garlic on GPx activity in cultured 
monocytes supematants 
Due to the proven beneficial role of allicin Irom garlic as a natural anti-oxidant 
in a range of pathological conditions, we opted to study its comparative effect 
on antioxidant state in supematants of 24 hours cultured monocytes from 
patients with osteoporosis and healthy individuals which served as controls. 
Monocytes were therefore, co-cultured for 24 hours with varying concentrations 
of allicin (0, 50, 100, 250, and 500ng/ml). Cultures were harvested and 
supematants obtained were subjected to GPx activity determination. 
Insignificant variation in the activity; 74.17, 76.63, 73.83, 75.38 and 76.27 U/mg 
protein was recorded for healthy individuals at above mentioned allicin 
concentrations (Figure 4). On the contrary, in case of osteoporosis patients 
(Figure 5), the GPx activity was found to increase in a dose-dependent manner 
from 29.43 U/mg protein, through 36.12,40.18, 50.08, 67.76 U/ mg protein at 0, 
50, 100, 250 and 500 ng/ml allicin. These results clearly prove allicin as an 
effective natural antioxidant capable of raising the depressed antioxidant state in 
case of osteoporosis. All values are mean ± SE, p<0.001 and n=6 in each study 
group. 
(5) Dose response effect of EGCG on GPx activity in monocyte culture 
supematants 
Since EGCG from green tea is a known natural antioxidant as well as an 
immuno-regulator, thus, its effect on GPx activity in monocyte culture 
supematants of healthy individuals and osteoporosis patients was also studied 
for a comparative analysis. 
Monocytes were co-cultured for 24 hours with varying doses of EGCG (0, 2, 5, 
10, 15 and 20 ng/ml). Supematants when subjected to GPx activity showed 
progressive up-regulation in a dose-dependent maimer fi-om 33.88 U/mg protein 
through 40.16, 48.67, 54.97, 70.03 and 74.32 U/ mg protein (Figure 6). On the 
contrary, 
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insignificant variation (71.04, 70.27, 71.40, 75.27, 74.15 and 76.38 U/mg 
protein) at above mentioned doses of EGCG was recorded in case of healthy 
individuals (Figure 7). Therefore, EGCG, together with allicin proved to be 
effective herbal antioxidant in osteoporosis. All values are mean ± SB, p<0.001 
and n=6 in each study group. 
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FIGURE 4: Dose response effect on GPx activity in monocytes cultured 
supernatants of healthy individuals, treated with AUicin (0-500ng/ml) for 24 
hours. Data represent mean ± S.E.M. of six independent experiments. p<0.001 was 
considered significant. 
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FIGURE 5: Dose response effect on GPx activity in monocytes cultured 
supernatants of osteoporosis patients, treated with Allicin (O-SOOng/ml) for 24 
hours. Data represent mean ± S.E.M. of six independent experiments. p<0.001 was 
considered significant. 
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FIGURE 6: Dose response effect on GPx activity in monocytes culture 
supernatants of osteoporosis patients, treated with EGCG (0-20 fig/ml) for 24 
hours. Data represent mean ± S.E.M. of six independent experiments. p<0.001 was 
considered significant. 
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FIGURE 7: Dose response effect on GPx activity in monocytes culture 
supernatants of healthy individuals, treated with EGCG (0-20 ^g/ml) for 24 
hours. Data represent mean ± S.E.M. of six independent experiments. p<0.001 was 
considered significant. 
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(6) Dose response effect of allicin on intramonocyte levels of glutathione (GSH) 
Thereafter, an attempt was also made to probe for any regulatory effect of 
varying doses of allicin (0, 50, 100, 250, and 500 ng/ml) on intramonocyte GSH 
levels in 24 hours monocyte cultures. Substantially low level (123.22 pg/ml) of 
intramonocyte GSH was recorded at 0 ng/ml allicin compared to healthy 
individuals' monocyte cultures (316.28 pg/ml). An appreciable and 
dose-dependent up-regulation of intramonocyte GSH levels through 169.02, 
198.9, 265.2 to 286.2 pg/ml was recorded for osteoporosis patients at 0, 50, 100, 
250, and 500 ng/ml allicin (Figure 8). On the contrary, insignificant variation 
was observed in case of healthy subjects; 315.22, 309.18, 305.12, 303.62 and 
305.23 pg/ml (Figure 9). Therefore, allicin efficiently raised the depressed thiol 
anti-oxidant state in osteoporosis study subjects. All values are mean ± SE, p< 
0.001 and n=6 in each study group. 
(7) Dose response effect of EGCG from green tea on intramonocyte glutathione 
(GSH) levels 
Also, effect of varying concentrations of EGCG (0, 2, 5, 10, 15 and 20 i^g /ml) 
on intramonocyte GSH levels in 24 hour monocyte cultures was investigated. 
Again, significantly reduced levels of intramonocyte GSH were recorded at 
0 ng/ml EGCG (118.57 pg/ml) in case of osteoporosis pafients when compared 
to healthy subjects (323.40 pg/ml), which thereafter, increased dose-dependently 
through 152.10, 168.10, 247.30, 259.43 to 279.65 pg/ml at 2, 5, 10, 15 and 
20 |ig /ml EGCG respectively (Figure 10). Insignificant variation was observed 
in case of healthy subjects; 304.70, 297.30, 303.13, 302.23, 299.54 and 
301.90 pg/ml at above mentioned doses of EGCG (Figure 11). Thus, EGCG can 
also be effectively used to improve the degenerating anti-oxidant state in the 
pathogenesis of osteoporosis. All values are mean ± SE, p<0.001 and n=6. 
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FIGURE 8: Dose response effect of Allicin (0-500 ng/ml) on Intramonocyte 
Glutathione (GSH) levels in 24 hours monocyte cultures of osteoporosis patients. 
Data represent mean ± S.E.M. of six independent experiments. p<0.001 was 
considered significant. 
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FIGURE 9: Dose response effect of Allicin (0-500 ng/ml) on Intramonocyte 
Glutathione (GSH) levels in 24 hours monocyte cultures of healthy individuals. 
Data represent mean ± S.E.M. of six independent experiments. p<0.001 was 
considered significant. 
Page 64 
Results 
400 
350 
300 
"E 250 
3 200 
i 150 
100 
50 
I Healthy Control • Osteoporosis Patients 
2 5 10 15 20 
EGCG (Mg/ml) 
FIGURE 10: Dose response effect of EGCG (0-20 ^g/I^l) on Intramonocyte 
Glutathione (GSH) levels, in 24 hours monocytes culture of osteoporosis patients. 
Data represent mean ± S.E.M. of six independent experiments. p<0.001 was 
considered significant. 
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FIGURE 11: Dose response effect of EGCG (0-20 jig/ml) on Intramonocyte 
Glutathione levels, in 24 houi^  monocytes culture of healthy subjects. Data 
represent mean ± S.E.M. of six independent experiments. p<0.001 was considered 
significant. 
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(8) Modulation of intramonocyte glutathione (GSH) levels 
Intracellular signaling via NFKB is known to be ROS sensitive and given the 
high oxidative stress in osteoporosis, monocytes from the study groups were 24 
hourly co-cultured with 10 mM NAC or 100 ng/ml SN50 or 100 i^g/ml SN50/M 
or 500 ng/ml allicin or 20 jxg/ml EGCG for comparative modulation of 
intramonocyte GSH levels. Control cultures (-) did not receive any treatment 
and revealed intramonocyte GSH levels of 314.50 and 129.61 pg/ml for 
osteoporosis and healthy individuals respectively (Figures. 12 and 13 
respectively). At 24 hours, NAC, a known anti-oxidant and SN50, an inhibitor 
of NFKB activation both up-regulated the intramonocyte GSH levels in cultures 
of osteoporosis patients (243.67 and 269.37 pg/ml respectively). However, 
SN50/M, an inactive analogue of SN50, at same concentration failed to cause 
any modulation in osteoporosis patients (139.29 pg/ml). Allicin, a natural anti-
oxidant and EGCG, a green tea polyphenol and also an immuno-regulator, was 
chosen for this modulation study. Interestingly, both allicin and EGCG 
appreciably up-regulated the intramonocyte GSH levels in osteoporosis patients 
(279.33 and 258.11 pg/ml respectively). When compared, it was much more 
potently than either NAC or SN50. Insignificant variation (302.10, 288.70, 
304.18, 288.92, 302.40 and 309.30 pg/ml) was recorded in case of healthy 
individuals with any of the modulating agent used here. These results 
collectively indicate that the down-regulated intramonocyte GSH levels in 
osteoporosis patients is NFKB mediated and that allicin and EGCG, both prove 
as potential natural and safer anti-oxidants in osteoporosis. All values are mean 
± SE, p<0.001 and n=6 in each of the study groups. 
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FIGURE 12: Comparative modulation study of Intramonocyte GSH levels of 
osteoporosis patients in 24 hour co-culture using NAC, SN50, SN50/M, Allicin 
and EGCG. (-) denotes no treatment. Data represent mean ± S.E.M. of six 
independent experiments. p<0.001 was considered significant. 
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FIGURE 13: Comparative modulation study of Intramonocyte GSH levels of 
healthy controls in 24 hour co-culture using NAC, SN50, SN50/M, AUicin and 
EGCG. (-) denotes no treatment. Data represent mean ± S.E.M. of six independent 
experiments. p<0.00] was considered significant. 
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(9) Determination of serum MDA levels in pre- and post-menopausal patients 
As a step further, following the results showing impaired antioxidant systems in 
osteoporosis patients as revealed by decreased GPx activity and reduced GSH 
levels, we measured the levels of a by-product of lipid peroxidation i.e., 
malondialdehyde (MDA) in the sera of osteoporosis patients to detect further 
signs of increased oxidative stress. In comparison to healthy group (7.51 ng/ml), 
the serum MDA values were found to be almost four times higher in 
osteoporosis patients (28.31 ng/ml) as depicted in Figure 14. All values are 
mean SE of six experiments i.e., n=6 and p<0.001 in each case. 
(10) Determination of MDA levels in culture supernatants of monocytes 
Adherent monocytes from PBMCs of all the study groups were cultured for 24 
hours and supernatants analysed for MDA levels which in osteoporosis patients 
stood to a near 3.6 times (30.83 ng/ml) the level found in healthy group 
(9.88 ng/ml) as depicted in Figure 15. Data represent mean SE of six 
experiments, p<0.001 in each case. Therefore, osteoporotic patients are indeed 
exposed to high oxidative stress as reflected by high levels of MDA both in 
serum as well as in supernatants of cultured monocytes. 
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FIGURE 14: MDA levels in serum of healthy controls and osteoporosis patients. 
Data represent mean ± S.E.M. of six independent experiments. p<0.001 was 
considered significant. 
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FIGURE 15: MDA levels in monocyte culture supematants of healthy 
individuals and osteoporosis patients. Data represent mean ± S.E.M. of six 
independent experiments. p<0.001 was considered significant. 
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(11) Dose response effect of allicin on MDA levels in supernatants of cultured 
monocytes 
Next, in order to find out if allicin could prove beneficial in overcoming the 
augmented oxidative stress so common in osteoporosis, monocytes obtained 
from the study groups were co-cultured for 24 hours with varying doses of 
allicin (0-500 ng/ml) and supernatants compared for MDA levels. As is evident 
from Figure 16, the MDA levels, ranging only from 6.18 ng/ml to 6.99 ng/ml in 
the supernatants of monocyte cultures of healthy subjects, remained more or less 
unaltered at all the concentrations of allicin used. While in case of osteoporosis 
patients, the MDA levels showed a dose-dependent decrease from 26.33 ng/ml 
when monocytes were cultured alone through 15.61, 13.21, 9.16 to as low as 
7.11 ng/ml when treated with 50, 100, 250, and 500 ng/ml allicin respectively 
(Figure 17). Therefore, at doses of 250 and 500 ng/ml allicin, MDA levels in 
osteoporosis patients were comparable to those found in healthy subjects 
thereby upholding potential antioxidant property of allicin in combating high 
oxidative stress in osteoporosis. All values are mean SE, n=6 in each study 
group and p<0.001 in each case. 
(12) Dose response effect of EGCG on MDA levels in monocyte culture 
supernatants 
Apart from the above, monocytes were similarly treated for 24 hours with 
varying doses of EGCG (0-20 |ig/ml) to explore if any positive impact EGCG 
would show in the pathogenesis of bone loss due to osteoporosis. Thus, the 
supernatants of the said cultures when analyzed for MDA levels, which showed 
a progressive down-regulation in osteoporosis patients from 27.93 ng/ml when 
monocytes were cultured alone and then through 21.62,17.21,13.14,10.11 to as 
only as 7.93 ng/ml when treated with 2, 5, 10, 15 and 20 i^ g/ml of EGCG 
respectively as shown in Figure 18. No significant variation was observed at any 
of the above mentioned EGCG doses in case of healthy group with MDA levels 
of 7.09, 7.28, 7.42, 7.39, 7.92, and 7.18 ng/ml respectively (Figure 19). All 
values are mean SE of n=6 in each study group and p<0.001 in each case. 
Therefore, EGCG once again proved to be efficient antioxidant in osteoporosis. 
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FIGURE 16: Dose response effect of Allicin (0-500 ng/ml) on MDA levels in 24 
hour monocyte culture supernatants of healthy subjects. Data represent mean ± 
S.E.M. of six independent experiments. p<0.001 was considered significant. 
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FIGURE 17: Dose response effect of AlUcin (0-500 ng/ml) on MDA levels in 24 
hour monocyte culture supernatants of osteoporosis patients. Data represent mean 
± S.E.M. of six independent experiments. p<0.001 was considered significant. 
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FIGURE 18: Dose response effect of EGCG (0-20 fig/ml) on MDA levels in 
monocyte supernatants of osteoporosis patients, cultured for 24 hours. Data 
represent mean ± S.E.M. of six independent experiments. p<0.001 was considered 
significant. 
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FIGURE 19: Dose response effect of EGCG (0-20 >ig/ml) on MDA levels in 
monocyte supematants of healthy individuals, cultured for 24 hours. Data 
represent mean ± S.E.M. of six independent experiments. p<0.001 was considered 
significant. 
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SECTION (B) IMMUNOLOGICAL STUDY BY ELISA 
(1) Determination of IL-ip levek in sera and supernatants of monocyte 
cultures of Osteoporosis patients and healthy individuals by ELISA 
Presence of high levels of pro-inflammatory cytokine IL-ip in osteoporosis is 
well established. Thus, an attempt was made to probe the levels of IL-lp in sera 
as well as monocyte culture supernatants of osteoporosis patients and results 
compared with those obtained from healthy subjects. ELISA results depicted in 
Figure 20 clearly show high basal levels of IL-lp in sera as well as monocyte 
culture supernatants of osteoporosis patients (181.16 pg/ml and 141.36 pg/ml 
respectively) compared to IL-ip secretion in sera (27.23 pg/ml) and healthy 
individuals (6.85 pg/ml). All values are mean ± SE; p<0.001 and n=8 in each 
study group. 
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FIGURE 20: Levels of IL-lp in serum and monocyte culture supernatants of 
healthy controls and osteoporosis patients. Data represent mean ± S.E.M. of eight 
independent experiments. p<0.001 was considered significant. 
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(2) Dose-response effect of allicin on expression of IL-lp in monocyte culture 
supernatants 
Monocytes of study group were cultured for 24 hours with varying 
concentrations of alHcin (0, 50, 100, 250 and 500 ng/ml). Cultures were 
harvested and supernatants obtained were subjected to ELISA for comparative 
evaluation of IL-ip secretion. As is evident from Figure 21, the secretion of 
IL-ip was found to decrease dose-dependently in osteoporosis patients from 
161.34 pg/ml through 136.11, 44.12, 30.21, 26.19 pg/ml at 0, 50, 100, 250 and 
500 ng/m] allicin respectively. In case of healthy subjects, low IL-ip secretion 
remained more or less unaffected, which were to the order of 4.51, 4.18, 5.63, 
3.56 and 4.25 pg/ml respectively at the above varying doses of allicin 
(Figure 22). All values are mean ± SE, p<0.001 and n=6 in each of the study 
groups. 
(3) Dose-response effect of EGCG from green tea on the expression of IL-ip in 
monocyte culture supernatants 
Thereafter, monocytes of study groups were similarly treated with varying 
concentrations of EGCG (0, 5, 10, 15 and 20 pg/ml). A similar response was 
observed with EGCG as was observed above with allicin. In case of 
osteoporosis patients, IL-ip secretion dose-dependently decreased from 169.12 
pg/ml thi-ough 144.36, 81.39, 44.26 and 29.11 pg/ml (Figure 23). In healthy 
individuals, 3.06, 4.35, 3.96, 3.36 and 3.19 pg/ml IL-ip secretion levels were 
recorded at the respective varying doses of EGCG (Figure 24). All data 
represent mean ± SE; p<0.001 and n=6 in each study groups. 
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FIGURE 21: Dose-response effect of varying doses of Allicin (0-500 ng/ml) on 
expression of IL-ip in 24 hour monocyte culture supernatants of osteoporosis 
patients. Data represent mean ± S.E.M. of six independent experiments. p<0.001 was 
considered significant. 
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FIGURE 22: Dose-response effect of varying doses of Allicin (0-500 ng/ml) on 
expression of IL-ip in 24 hour monocyte culture supematants of healthy 
subjects. Data represent mean ± S.E.M. of six independent experiments. p<0.001 was 
considered significant. 
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FIGURE 23: Dose-response effect of varying doses of EGCG (0-20 jig/ml) on 
expression of IL-lp, in 24 hour culture monocyte culture supernatants of 
osteoporosis patients. Data represent mean ± S.E.M. of six independent experiments. 
p<0.001 was considered significant. 
Page 83 
Results 
10 
^ 8 
"5 
Be 
-2 4 
— 2 
10 15 20 
EGCG (Mg/ml) 
FIGURE 24: Dose-response effect of varying doses of EGCG (0-20 fig/ml) on 
expression of IL-ip, in 24 hour monocyte culture supernatants of healthy 
subjects. Data represent mean ± S.E.M. of six independent experiments. p<0.001 was 
considered significant. 
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(4) Modulation of IL-ip secretion in monocyte culture supernatants 
To compare the modulation in IL-lp secretion, monocytes were co-cultured with 
10 mM NAC, or 100 ng/ml SN50, or 100 i^g/ml SN50/M, or 500 ng/ml allicin, 
or 20 ng/ml EGCG. Control cultures (-) in each study group did not receive any 
treatment and revealed IL-ip basal levels of 6.27 and 164.19 pg/ml for healthy 
subjects (Figure 25), and osteoporosis patients (Figure 26) respectively. At 
24 hrs, NAC, a known anti-oxidant and SN50, an inhibitor of NFKB activation 
both down-regulated the IL-lp secretion in osteoporosis patients (55.14 and 
40.61 pg/ml respectively). However, SN50/M, an inactive analogue of SN50 
failed to show any modulation in osteoporosis patients (162.32 pg/ml). While 
allicin, a natural anti-oxidant and EGCG, a green tea polyphenol and also an 
immuno-regulator, chosen in this modulation study, both produced an 
appreciable down-regulation of IL-ip secretion in osteoporosis patients (29.16 
and 25.22 pg/ml respectively), which was found to be much more effectively 
than either NAC or SN50. In case of healthy individuals, insignificant variation 
was observed with any of the modulating agents. These results while indicating 
that the secretion of IL~ip is NFKB mediated prove efficacy of allicin and 
EGCG as natural and safer alternative or adjunct as anti-bone resorptive agents. 
All values are mean ± SE; p<0.001 and n=6 in each study group. 
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FIGURE 25: Comparative modulation study of levels of IL-ip in healthy 
subjects, as controls in 24 hour co-culture of monocyte supematants using NAC, 
SN50, SN50/M, Allicin and EGCG. (-) denotes no treatment. Data represent mean 
± S.E.M. of six independent experiments. p<0.001 was considered significant. 
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FIGURE 26: Comparative modulation study of levels of IL-ip in osteoporosis 
patients in 24 hour co-culture of monocyte supematants, using NAC, SN50, 
SN50/M, AUicin and EGCG. (-) denotes no treatment. Data represent mean ± S.E.M. 
of six independent experiments. p<0.001 was considered significant. 
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SECTION (C) BONE MARKER STUDY BY QUANTITATIVE 
'REAL TIME RT-PCR 
In this section, attempt has been made for comparative characterization of monocytes 
at the gene level from osteoporosis patients and compared to those of healthy 
individuals with respect to bone markers like TNF-a and OPG. 
(1) Expression of Bone Marker TNF-alpha mRNA by real-time RT-PCR 
PBMCs were isolated from the blood of normal healthy individuals and 
osteoporosis patients to obtain adherent monocytes as described in methods. 
Monocytes from osteoporosis patients were then subjected to TNF-a mRNA 
evaluation by real-time RT-PCR and compared Mdth the values of TNF-a 
mRNA copy number recorded in monocytes from healthy subjects. As is evident 
from Figure 27, in comparison to healthy subjects' monocytes, those from 
osteoporosis patients revealed the presence of high basal levels of TNF-a 
mRNA copy number which was to the order of 7.16E+08 (p<0.001) These data, 
therefore, revealed significantly high basal levels of TNF-a mRNA in the 
monocytes of osteoporosis patients. All values are mean ± SE of six experiments 
in each study group. 
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FIGURE 27: Real Time RT-PCR for TNF-a mRNA expression in monocyte 
cultures of healthy individuals and osteoporosis patients. Expression of TNF-a 
was corrected to host 18S rRNA and expressed as copies of TNF-a in lO'" copies of 
R18 (equivalent to ]x 10^  cells). Data represent mean ± S.E.M. of six independent 
experiments. p<0.001 was considered significant. 
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(2) Expression of Bone Marker OPG mRNA by real-time RT-PCR 
Next, monocytes from the study group were subjected to OPG mRNA 
evaluation by real-time RT-PCR. In case of osteoporosis patients, the data 
obtained revealed higher basal levels of OPG mRNA copy number which was 
~ 8.3 logs (p<0.001) the healthy subjects level (Figure 28). This resuh therefore, 
indicated higher basal level expression of OPG mRNA in osteoporosis patient's 
PBMCs. 
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FIGURE 28: Real Time RT-PCR for OPG mRNA expression in monocyte 
cultures of healthy individuals and osteoporosis patients. Expression of OPG was 
corrected to host 18S rRNA and expressed as copies of OPG in lO"* copies of R18 
(equivalent to Ix 10^  cells). Data represent mean ± S.E.M. of six independent 
experiments. p<0.001 was considered significant. 
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(3) Dose response effect of allicin from garlic and EGCG from green tea on 
human house keeping gene R18 
In view of proven health benefits of garHc since ancient times, we chose here to 
study action of allicin, an active component of garlic and also EGCG, the 
biologically active compound of green tea, on monocytes isolated from PBMCs 
of the study groups. First, an attempt was made to probe the effect of allicin as 
well as EGCG, if any, on the human house keeping gene Rl 8 whereby it was 
observed that neither allicin (0-500 ng/ml) nor EGCG (0-20 ^g/ml), at any of 
their respective concentrations when these were used to co-culture the 
monocytes, had any significant effect on the expression of human house keeping 
gene R18 as revealed by quantitative real-time RT-PCR (Figure 29 and 
30 respectively for allicin and EGCG). 
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FIGURE 29: Real Time RT-PCR for dose response effect of Allicin on the 
expression of human house keeping gene R18. Data represent mean ± S.E.M. of six 
independent experiments. p<0.001 was considered significant. 
Page 93 
Results 
l.OOE+10 
O" l.OOE+ra 
< 
tt l.OOE+06 
gj l.OOE+04 
00 
l.OOE+02 
l.OOE+00 
2 5 10 
EGCG (Mg/ml) 
15 20 
FIGURE 30: Real Time RT-PCR for dose response effect of EGCG on the 
expression of human house keeping gene R18. Data represent mean ± S.E.M. of six 
independent experiments. p<0.001 was considered significant. 
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(4) Dose response effect of allicin on TNF-a expression 
Here, we first started with allicin to investigate its action upon TNF-a mRNA 
gene expression for which purpose adherent monocytes from PBMCs of 
osteoporosis patients and healthy subjects were co-cultured with varying 
concentrations of allicin (0-500 ng/ml) for 24 hours. Cultures devoid of allicin 
i.e., at 0 ng/ ml served as control. Monocytes were then subjected to TNF-a 
mRNA evaluation by real-time RT-PCR. It is evident from Figure 31, the 
expression of TNF-a mRNA was dose-dependent showing significant 
downregulation in its copy number in case of osteoporosis patients from 
7.14E+08 in untreated monocytes through 0.53 logs, ~ 3.8 logs, ~ 4.9 logs to 
~ 5.8 logs when monoc)'tes were treated with 50, 100, 250, and 500 ng/ml 
allicin respectively. However, no significant variation was observed in case of 
healthy individuals whereby expression tended to ~ 0.05 logs, 0.6 logs, 0.6 logs 
and 0.7 logs of that observed in untreated monocytes. The data in this 
experiment prove allicin as an effective natural suppressor of augmented TNF-a 
mRNA levels in osteoporosis whereby it can be used as a potent anti 
bone-resorptive agent in this kind of bone pathogenesis. Data represent mean 
± SE of six experiments in each study group i.e., n=6 and p<0.001 in each case. 
(5) Dose response effect of allicin on OPG mRNA expression 
Allicin was also used to check its effect on OPG mRNA expression. Thus, 
adherent monocytes from PBMCs of osteoporosis patients and healthy subjects 
were co-cultured with various doses of allicin (0-500 ng/ml) for 24 hours. 
Monocytes were subjected to OPG mRNA evaluation by real-time RT-PCR and 
results depicted in Figure 32. As evident, the expression of OPG mRNA showed 
dose-dependent downregulation with increasing doses of allicin. In case of 
osteoporosis patients, the OPG mRNA copy number was recorded as 3.64E+09 
when monocytes were cultured alone. Thereafter it showed a downregulation of 
as much as 0.6 logs, ~ 4 logs, -5.6 logs and ~ 6.3 logs when monocytes were 
cultured with 50,100,250, and 500 ng/ml allicin respectively. 
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No significant change with these concentrations was observed in case of heakhy 
individuals whereby expression tended to 0.05 logs, 0.07 logs, 0.09 logs and 
0.15 logs starting from 2.66E+00 (untreated monocytes). Data represent mean 
± SE of six experiments (n=6) in each study group and p<0.001. 
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FIGURE 31: Real Time RT PCR for dose response effect of AUicin (0-500 ng/ml) 
on the expression of TNF-a mRNA from PBMCs of healthy individuals and 
osteoporosis patients, cultured for 24 hours. Cultures receiving 0 ng/ml allicin 
served as controls. Expression of TNF-a was corrected to host 18S rRNA and 
expressed as copies of TNF-a in lO"^  copies of R18 (equivalent to Ix 10^  cells). Data 
represent mean ± S.E.M. of six independent experiments. p<0.001 was considered 
significant. 
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(6) FIGURE 32: Real Time RT PCR for dose response effect of Allicin (0-500 
ng/ml) on OPG mRNA expression from PBMCs of osteoporosis patients 
and healthy subjects, cultured for 24 hours. Cultures receiving 0 ng/ml allicin 
served as controls. Expression of TNF-a was corrected to host 18S rRNA and 
expressed as copies of TNF-a in lO' copies of R18 (equivalent to 1 x 10^ cells). 
Data represent mean ± S.E.M. of six independent experiments. p<0.001 was 
considered significant. 
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(7) Dose response effect of EGCG on TNF-a expression 
Thereafter, it was also attempted to probe the effect of varying concentrations of 
EGCG (0-20 ng/ml) on the expression of TNF-a mRNA in 24 hour cultures of 
PBMCs isolated fi-om osteoporosis patients and healthy subjects. As is evident 
in Figure 33, monocytes when subjected to TNF-a mRNA evaluation by 
real- time RT-PCR showed dose-dependence on EGCG in all study groups. In 
case of osteoporosis patients, significant downregulation of TNF-a mRNA copy 
number of as much as 0.22 logs, 3.33 logs, ~ 5.4 logs, 5.6 logs and 5.95 logs 
was observed in monocytes treated with 2, 5, 10, 15 and 20 ng/ml of EGCG 
respectively when compared to untreated monocytes. 
On the contrary, no significant change in gene expression (0.08 logs, 1.03 logs, 
1.17 logs. 1.19 and 1.24 logs compared to untreated monocytes) was observed in 
case of healthy subjects at any of the concentrations of EGCG used. The data in 
this result point to EGCG especially at 10, 15 and 20 \i%Jm\ doses as effective 
natural immunoregulator that can be used against the pathogenesis of bone loss 
in osteoporosis. All values are mean ± SE of six experiments (n=6) (p<0.001). 
(8) Dose response effect of EGCG on OPG mRNA expression 
Thereafter, change in the expression of OPG mRNA with EGCG was also 
probed, whereby varying doses of EGCG (0-20 }xg/ml) were used to co-culture 
the monocytes isolated from PBMCs of osteoporosis patients and healthy 
subjects for 24 hours. Monocytes were then subjected to OPG mRNA evaluation 
by real-time RT-PCR, wherein the results are depicted in Figure 34. As evident, 
the expression of OPG mRNA showed dose-dependent downregulation with 
increasing doses of EGCG. In case of osteoporosis patients, the OPG mRNA 
copy number was recorded as 3.05E+09 when monocytes were cultured alone, 
thereafter a downregulation of as much as ~ 0.53 logs, 2.04 logs, -3 .5 logs, 
4.4 logs and 5.3 logs was recorded at 2, 5, 10, 15 and 20 ng/ml EGCG 
co-culture respectively. Insignificant variation in gene expression in case of 
healthy subjects from 1.94E+00 
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at 0 i^g/ml EGCG, through 0.035 logs, 0.063 logs, 0.077 logs, 0.069 logs to 
0.089 logs was observed at these doses of EGCG respectively. These results 
indicated that EGCG significantly down regulated the OPG mRNA expression 
in osteoporosis patients. All data are mean ± SE of six experiments (p<0.001). 
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FIGURE 33: Real time RT PCR for dose response effect of EGCG (0-20 ^g/ml) 
on TNF- a mRNA expression, from PBMCs of healthy individuals and 
osteoporosis patients, cultured for 24 hours. Cultures receiving 0 |ig/ml EGCG 
served as controls. Expression of TNF-a was corrected to host 18S rRNA and 
expressed as copies of TNF-a in 10'° copies of R18 (equivalent to 1 x 10*' cells). Data 
represent mean ± S.E.M. of six independent experiments. p<0.001 was considered 
significant. 
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FIGURE 34: Real time RT PCR for dose response effect of EGCG (0-20 ^g/ml) 
on OPG mRNA expression, from PBMCs of healthy individuals and osteoporosis 
patients, cultured for 24 hours. Cultures receiving 0 fig/mi EGCG served as 
controls. Expression of OPG was corrected to host 18S RNA and expressed as copies 
of OPG in 10'° copies of R18 (equivalent to Ix 10^ cells). Data represent mean ± 
S.E.M. of six independent experiments. p<0.001 was considered significant. 
Page 102 
Results 
(9) Effect of lOmM NAC on TNF-a and OPG mRNA expression 
Next, we used N-acetyl cysteine (NAC) which is a known anti-oxidant to effect 
the change in expression of TNF-a and OPG mRNA extracted from monocyte 
fraction of peripheral blood collected from osteoporosis patients. This was done 
in order to compare the effects as revealed by allicin and EGCG in our study on 
the expression of TNF-a and OPG mRNA in osteoporosis patient monocytes. 
Therefore, monocytes were either treated or untreated with 10 mM NAC for 
24 hours and then subjected to evaluation of TNF-a and OPG mRNA by 
real-time RT-PCR. As is evident in Figure 35, untreated monocytes revealed 
higher expression of both TNF-a mRNA (~ 7.8 logs) and OPG mRNA 
(~ 8.4 logs) in osteoporosis patients while treatment with 10 mM NAC caused a 
downregulation of ~ 4.6 logs in TNF-a mRNA level and 4.2 logs in OPG 
mRNA expression level in this study group. While in previous results, allicin 
and EGCG have revealed more potent effect on both the genes expression. Data 
in this figure are mean ± SE of six individual experiments; p<0.001. 
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FIGURE 35: Real time RT PCR for effect of 10 mM NAC on TNF-a mRNA and 
OPG mRNA expression, in monocyte cultures of osteoporosis patients, cultured 
for 24 hours. Expression of TNF-a and OPG was corrected to host 18S rRNA and 
expressed as copies of TNF-a and OPG in lO' copies of R18 (equivalent to 
1x10^ cells). Data represent mean ± S.E.M. of six independent experiments. p<0.001 
was considered significant. 
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SECTION (D) OSTEOCLAST AND BONE MARKER STUDY 
BY TRAP AND ELISA 
(1) GeneratioDi of Human Osteoclast Precursors from Peripheral Blood 
Mononuclear Cells (PBMCs) 
Peripheral blood mononuclear cells (PBMCs) were used directly for the 
generation of osteoclast precursors after centriftigation with Ficoll-Hypaque. 
After the 3 day culture duration in osteoclastogenic medium (a-MEM culture 
medium supplemented with 10% FCS, lOOU/ml penicillin, 
100 ng/ml streptomycin, 50ng/ml M-CSF and 25ng/ml RANKL), 
multinucleated osteoclast precursors were observed to appear and the number 
increased lafter 5 days of culture, as revealed by Tartrate Resistant Acid 
Phosphatase (TRAP) staining (Figures 36{a,b,c} and 37{a,b,c}). However, there 
was no appearance of osteoclast precursors after 24 h (1 day) of culture (data not 
shown). The number of multinucleated preosteoclasts, arising from PBMCs 
isolated from the blood of normal healthy individual (data not shown) and 
osteoporotic patients (Figure 36, 37), were counted by TRAP staining. 
Interestingly, we observed an individual variation in osteoclast generation from 
different donors as depicted by different number of multinucleated cells in 
Figure 36 and Figure 37. 
Page 105 
Results 
zn 
! ti 
I & 
' 00 
T 
;n 
a 
'^ 
• c 
S3 
a 
u 
3 
3 
S 
t>-
O 
o 
z 
80 
/U 
60 
50 
40 
30 
20 
10 
0 
10 
Patient number 
FIGURE 36 (a): Individual variation in generation of human osteoclast 
precursors from PBMCs of osteoporosis patients (1 to 10), cultured for 3 days in 
osteoclastogenic medium, quantified as TRAP (+ve) multinucleated cells as 
assessed by TRAP staining. The results are shown as means ± SEM. 
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FIGURE 36 (b) : Individual variation in generation of human osteoclast 
precursors from PBMCs of osteoporosis patients (11 to 20), cultured for 3 days 
in osteoclastogenic medium, quantified as TRAP (+ve) multinucleated cells as 
assessed by TRAP staining. The results are shown as means ± SEM. 
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FIGURE 36 (c) : Individual variation in generation of human osteoclast 
precursors from PBMCs of osteoporosis patients (21 to 30), cultured for 3 days 
in osteoclastogenic medium, quantified as TRAP (+ve) multinucleated cells as 
assessed by TRAP staining. The results are shown as means ± SEM. 
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FIGURE 37 (a): Individual variation in generation of human osteoclast 
precursors from PBMCs of osteoporosis patients (1 to 10), cultured for 5 days in 
osteoclastogenic medium, quantified as TRAP (+ve) multinucleated cells as 
assessed by TBL4P staining. The results are shown as means ± SEM. 
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FIGURE 37 (b): Individual variation in generation of human osteoclast 
precursors from PBMCs of osteoporosis patients (11 to 20), cultured for 5 days 
in osteoclastogenic medium, quantified as TRAP (+ve) multinucleated cells as 
assessed by TFIAP staining. The results are shown as means ± SEM. 
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FIGURE 37 (c): Individual variation in generation of human osteoclast 
precursors from PBMCs, of osteoporosis patients (21 to 30), cultured for 5 days 
in osteoclastogenic medium, quantified as TRAP (+ve) multinucleated cells as 
assessed by TRAP staining. The results are shown as means ± SEM. 
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(2) Effect of Epigallocatechiii gailate (EGCG) and Allicin on the Generation of 
Human Osteoclasts 
Interestingly, we observed that co-culturing of PBMCs with EGCG (20 jig/ml) 
or Allicin (500 ng/ml) in osteoclastogenic medium for 3 and 5 days resulted in 
an appreciable amount of reduction in appearance of multinucleated osteoclast 
precursors (Figure 38 {a,b,c} and 39 {a,b,c} for EGCG and Figures 40 {a,b,c} 
and Figures 41 {a,b,c} for Allicin respectively). Hence, this reflects the potential 
of EGCG jmd allicin to exert regulatory effect in osteoclast generation and 
differentiation. The above dose of EGCG and Allicin was selected after 
performing dose response experiment, where TRAP assay revealed a linear 
suppression in the formation of multinucleated cells was observed (Figure 42 
and Figure 43 respectively). Nearly 20-25% suppression in appearance of 
multinucleated cells was observed in cultures receiving 15 fig/ml and 20 ng/ml 
of EGCG relative to control cultures devoid of any EGCG (Figure 42). 
Interestingly, around 30-35% suppression in appearance of multinucleated cells 
was observed in cultures receiving 250 ng/ml and 500 ng/ml of allicin relative to 
control cultures devoid of any allicin (Figure 43). 
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FIGURE 38 (a): Dose dependant reduction in appearance of multinucleated 
osteoclast precursors, from different donors (osteoporosis patient number 
1 to 10), co-cultured with and without EGCG (20fig/ml) in osteoclastogenic 
medium for 3 days. The results are shown as means ± SEM. 
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FIGURE 38 (b): Dose dependant reduction in appearance of multinucleated 
osteoclast precursors, from different donors (osteoporosis patient number 
11 to 20), co-cultured with and without EGCG (20^g/ml) in osteoclastogenic 
medium for 3 days. The results are shown as means ± SEM. 
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FIGURE 38 (c): Dose dependant reduction in appearance of multinucleated 
osteoclast precursors, from different donors (osteoporosis patient number 
21 to 30), co-cultured with and without EGCG (20^g/ml) in osteoclastogenic 
medium for 3 days. The results are shown as means ± SEM. 
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FIGURE 39 (a): Dose dependant reduction in appearance of multinucleated 
osteoclast precursors, from diiTerent donors (osteoporosis patient number 
1 to 10), co-cultured with and without EGCG (20|iig/ml) in osteoclastogenic 
medium for 5 days. The results are shown as means ± SEM. 
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FIGURE 39 (b): Dose dependant reduction in appearance of multinucleated 
osteoclast precursors, from different donors (osteoporosis patient number 
11 to 20), co-cuitured with and without EGCG (20|iig/ml) in osteoclastogenic 
medium for 5 days. The results are shown as means ± SEM. 
Page 117 
Results 
450 
I Without EGCG • With EGCG 
21 22 23 24 25 26 27 
Patient Number 
28 29 30 
FIGURE 39 (c): Dose dependant reduction in appearance of multinucleated 
osteoclast precursors, from different donors (osteoporosis patient number 
21 to 30), co-cultured with and without EGCG (20^g/ml) in osteoclastogenic 
medium for 5 days. The results are shown as means ± SEM. 
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FIGURE 40 (a): Dose dependant reduction in appearance of multinucleated 
osteoclast precursors, from different donors (osteoporosis patient number 
1 to 10), co-cultured with and without, AUicin (500 ng/ml) in osteoclastogenic 
medium for 3 days. The results are shown as means ± SEM. 
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FIGURE 40 (b): Dose dependant reduction in appearance of multinucleated 
osteoclast precursors, from different donors (osteoporosis patient number 
11 to 20), co-cultured with and without, Allicin (500 ng/ml) in osteoclastogenic 
medium for 3 days. The results are shown as means ± SEM. 
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FIGURE 40 (c): Dose dependant reduction in appearance of multinucleated 
osteoclast precursors, from different donors (osteoporosis patient number 
21 to 30), co-cultured with and without, Allicin (500 ng/ml) in osteoclastogenic 
medium for 3 days. The results are shown as means ± SEM. 
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FIGURE 41 (a): Dose dependant reduction in appearance of multinucleated 
osteoclast precursors, from different donors (osteoporosis patient number 
1 to 10), co-cultured with and without, Allicin (500 ng/ml) in osteoclastogenic 
medium for 5 days. The results are shown as means ± SEM. 
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FIGURE 41 (b): Dose dependant reduction in appearance of multinucleated 
osteoclast precursors, from different donors (osteoporosis patient number 
11 to 20), co-cultured with and without, Allicin (500 ng/ml) in osteoclastogenic 
medium for 5 days. The results are shown as means ± SEM. 
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FIGURE 41 (c): Dose dependant reduction in appearance of multinucleated 
osteoclast precursors, from different donors (osteoporosis patient number 
21 to 30), co-cultured with and without, Allicin (500 ng/ml) in osteoclastogenic 
medium for 5 days. The results are shown as means ± SEM. 
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FIGURE 42: Dose dependant suppression in appearance of multinucleated cells 
treated with EGCG (0-20 ^g/ml) as assessed by TRAP assay. NT denotes no 
treatment (Control). Data represent mean ± S.E.M. of three independent experiments. 
p<0.001 was considered significant. 
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FIGURE 43: Dose dependant suppression in appearance of multinucleated cells 
treated with Allicin (0-500 ng/ml) as assessed by TRAP assay. NT denotes no 
treatment (Control). Data represent mean ± S.E.M. of three independent experiments. 
p<0.001 was considered significant. 
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(3) Determination of Human sRANKL levels in culture supematants of healthy 
controls and osteoporosis patients 
Apart from the above, an attempt was also made to probe the levels sRANKL in 
cuhure supematants of healthy controls (n=6) and osteoporosis patients (n=6) by 
ELISA. In comparison to healthy controls (P<0.01), patient's cultures exhibited 
aroimd 9-fold augmented levels of sRANKL (pg/ml; P<0.001) (Figure 44). 
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FIGURE 44: Levels of Human sRANKL in culture supematants of healthy 
controls and osteoporosis patients as depicted by ELISA. Data represent mean 
± S.E.M. of six independent experiments. p<0.001 was considered significant. 
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(4) Dose response effect of allicin on sRANKL levels in culture supernatants of 
healthy controls and osteoporosis patients 
Monocytes of study groups were treated with varying concentrations of Allicin 
(0, 50, 100, 250 and 500 ng/ml). In case of osteoporosis patients, sRANKL 
secretion dose-dependently decreased from 30.68 pg/ml at through 25.36, 18.12, 
9.56 and 4.01 pg/ml with 50, 100, 250 and 500 ng/ml allicin respectively 
(Figure 45; P<0.001). On the contrary, healthy controls exhibited in between 
1.33 - 3.2 pg/ml of RANKL (data not sure). Next, after dose response 
evaluation, an attempt was also made to re-check the data by co-culturing with 
the maximum dose of allicin (500 ng/ml) selected in the study, and that, similar 
results were observed to the one's observed above in dose response experiments 
at the maximum dose (Figure 46; P<0.001). All data represent mean ± SE; 
p<0.001 and n=6 in each study groups. 
(5) Computational evaluation of allicin-induced percent suppression in the 
secretion of sRANKL in culture supernatants of osteoporosis patients 
Thus, computation of the data revealed that allicin down regulated / suppressed 
the secretion of sRANKL by around 17.34%, 40.93%, 68.83% and 86.92% with 
50, 100, 250 and 500 ng/ml allicin respectively (Figure 47). The IC50 was 
computed out to be in between 100 -125 ng/ml. 
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FIGURE 45: Dose response effect of AIHcin (0-500 ng/ml) on sRANKL levels in 
culture supernatants of osteoporosis patients. No or negligible effect was observed 
in healthy controls (data not shown). Data represent mean ± S.E.M. of six 
independent experiments. p<0.001 was considered significant. 
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FIGURE 46: Level of Human sRANKL in monocyte culture supernatants of 
various healthy individuals and osteoporosis patients that were co-cultured with 
the maximum dose (500ng/ml) of Allicin for five days. Data represent mean 
± S.E.M. of six independent experiments. p<0.001 was considered significant. 
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FIGURE 47: Computational evaluation of AUicin-induced percent suppression in 
the secretion of sRANKL in culture supematants of osteoporosis patients. The 
results are shown as means ± SEM. 
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(6) Dose response effect of EGCG on sRANKL levels in culture supematants of 
healthy controls and osteoporosis patients 
Similarly, monocytes of study groups were treated with varying concentrations 
of EGCG (0, 2, 5, 10, 15 and 20 |ig/ml). In case of osteoporosis patients, 
sRANKL secretion was found to dose-dependently decrease from 32.65 pg/ml 
at through 27.81, 22.45, 17.29, 13.07 and 9.44 pg/ml with 2, 5, 10, 15 and 
20 \ig/m\ EGCG respectively (Figure 48; P<0.001). On the contrary, healthy 
controls exhibited in between 1.3 - 3.2 pg/ml of RANKL (data not sure). Next, 
after dose response evaluation, an attempt was also made to re-check the data by 
co-culturing with the maximum dose of EGCG (20 |iig/ml) selected in the study, 
and that, similar results were observed to the one's observed above in dose 
response experiments at the maximum dose (Figure 49; P<0.001). All data 
represent mean ± SE; p<0.001 and n=6 in each study groups. 
(7) Computational evaluation of EGCG-induced percent suppression in the 
secretion of sRANKL in culture supematants of osteoporosis patients 
Computational analysis of the data revealed that EGCG down regulated / 
suppressed the secretion of sRANKL by around 14.82%, 31.24%, 47.04%, 
59.96% and 71.08% with 2, 5, 10, 15 and 20 ^g/ml EGCG respectively 
(Figure 50). The IC50 was computed out to be in between 7.5-10 |ig/ml of 
EGCG. 
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FIGURE 48: Dose response effect of EGCG (0-20»ig/ml) on sRANKL levels in 
culture supernatants of osteoporosis patients. No or negligible effect was observed 
in healthy controls (data not shown). Data represent mean ± S.E.M. of six 
independent experiments. p<0.001 was considered significant. 
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FIGURE 49: Level of Human sRANKL in monocyte culture supernatants of 
various healthy individuals and osteoporosis patients that were co-cultured with 
the maximum dose (20^g/ml) of EGCG for five days. Data represent mean 
± S.E.M. of six independent experiments. p<0.001 was considered significant. 
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FIGURE 50: Computational evaluation of EGCG-induced percent suppression 
in the secretion of sRANKL in culture supernatants of osteoporosis patients. The 
results are shown as means ± SEM. 
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(8) Modulation study of sRANKL 
Next, an attempt was also made to carry out modulation of sRANKL in the 
presence or absence of TNF-alpha (2 ng/ml) along with allicin (500 ng/ml) or 
EGCG (20 ]iglm\). Results show that there was negligible effect of TNF-alpha 
alone or with a combination of both TNF-alpha and allicin on healthy control 
cultures in comparison to untreated cultures (Figure 51). On the contrary, 
patient's samples / cultures exhibited sRANKL levels to the order of 31.39 
pg/ml (P<0.001), which in turn was found to be augmented to 43.24 pg/ml 
(P<0.001) in patient cultures receiving 2 ng/ml TNF-alpha (Figure 51). 
Interestingly, patient's cultures receiving a combination of both TNF-alpha 
(2 ng/ml) and allicin (500 ng/ml) exhibited an appreciable down-regulation / 
suppression in the secretion of sRANKL (12.28 pg/ml; P<0.001) (Figure 51). 
Similarly, an attempt was also made to carry out modulation of sRANKL in the 
presence or absence of TNF-alpha (2 ng/ml) along with EGCG (20 ng/ml). 
Results show that there was negligible effect of TNF-alpha alone or with a 
combination of both TNF-alpha and EGCG on healthy control cultures in 
comparison to untreated cultures (Figure 52). On the contrary, patient's samples 
/ cuUures exhibited sRANKL levels to the order of 31.39 pg/ml (P<0.001), 
which in turn was found to be augmented to 43.24 pg/ml (P<0.001) in patient 
cultures receiving 2 ng/ml TNF-alpha (Figure 52). Interestingly, patient's 
cultures receiving a combination of both TNF-alpha (2 ng/ml) and EGCG 
(20 jig/ml) exhibited an appreciable down-regulation / suppression in the 
secretion of sRANKL (17.54 pg/ml; P<0.001) (Figure 52). Thus, in the above 
depicted modulation study wherein TNF-alpha was co-cultured along with either 
allicin or EGCG, computational analysis of the data revealed that allicin 
inhibited the secretion of sRANKL by around 60% whereas EGCG inhibited the 
same by around 44%. 
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FIGURE 51: Level of human sRANKL in culture supernatants of monocyte 
cultures of osteoporosis patients that were co-cultured with or without 2 ng/ml of 
TNF-a or with a combination of 2 ng/ml TNF-o and 500 ng/ml of Allicin for five 
days. p<0.001 was considered significant. 
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FIGURE 52: Level of Human sRANKL in culture supernatants of monocyte 
cultures of osteoporosis patients that were co-cultured with or without 2 ng/ml of 
TNF-a or with a combination of 2 ng/ml TNF-a and 20 ftg/ml of EGCG for 
five days. p<0.001 was considered significant. 
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(9) Visualization of multinucleated cells / osteoclasts by TRAP assay 
Monocyte cultures from healthy control as well as that of osteoporosis patient 
were co-cultured without or with 500 ng/ml of allicin and 20 ^g/ml of EGCG 
respectively for 5 days. Similarly, one of the cultures from patient received 
2 ng/ml TNF-alpha. The detection of TRAP activity was performed using test 
kits from Sigma according to the manufacturer's instructions as described in 
methods. As evident from Figure 53, healthy confrol monocyte cultures did not 
show any multinucleated cells/osteoclasts, whereas those from osteoporosis 
patient exhibited appreciable number of multinucleated cells/osteoclasts 
(Figure 54). Interestingly, monocyte cultures of 5 days for osteoporosis patient 
that were co-cultured with 2 ng/ml of TNF-alpha exhibited an enhanced number 
of multinucleated cells/osteoclasts (Figure 55), when compared to cultures 
devoid of any TNF-alpha as was evident from the above said Figure 54. 
Next, in monocyte cultures of osteoporosis patient, when co-cultured with 
500 ng/ml of allicin and 20 i^ g/ml of EGCG respectively for 5 days the TRAP 
assay data showed that both 500 ng/ml allicin (Figure 56) as well as 20 ^g/ml 
EGCG (Figure 57), inhibited / suppressed / down-regulated the formation of 
multinucleated cells/osteoclasts. The suppression was clearly more in cultures 
receiving allicin in comparison to EGCG. 
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FIGURE 53: Normal healthy human monocytes were cultured for 5 days as 
described in methods. No multinucleated cells were detected. 
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FIGURE 54: Human monocytes from osteoporosis patients were cultured for 5 
days as described in methods, and thereafter subjected to TRAP staining. 
Appreciable numbers of multinucleated cells were observed. 
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FIGURE 55: Human monocytes from osteoporosis patients were co-cultured 
with 2 ng/ml TNF-alpha for 5 days as described in methods, and thereafter 
subjected to TRAP staining. An enhanced number of multinucleated cells were 
observed in comparison to cultures devoid of TNF-alpha. 
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FIGURE 56: Human monocytes from osteoporosis patients were co-cultured 
with 500 ng/ml allicin for 5 days as described in methods, and thereafter 
subjected to TRAP staining. An appreciably reduced number of multinucleated 
cells were observed in comparison to cultures devoid of allicin. 
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FIGURE 57: Human monocytes from osteoporosis patients were co-cultured 
with 20 ^g/ml EGCG for 5 days as described in metliods, and thereafter 
subjected to TRAP staining. An appreciably reduced number of multinucleated 
cells were observed in comparison to cultures devoid of EGCG. 
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Osteoporosis is characterized by low bone mass and microarchitectural deterioration 
of bone tissue, increasing susceptibility to fracture (Heinemann DF, 2000). Although 
osteoporosis is often described as a silent disease because it is typically asymptomatic 
until a fracture occurs, the disease negatively and significantly impacts morbidity and 
mortality as it can lead to severe pain, deformity, disability, and death (Heinemaim 
DF, 2000; Salkeld et al., 2000). While traditionally considered a condition afflicting 
predominantly postmenopausal women, osteoporosis is also an under recognized 
disorder in men (Ebeling PR, 2008; Adier RA., 2011) as analysis of hip fracture 
incidence indicates that one-third occur in men (Burge et al., 2007). As compared to 
females, males often develop fractures 10 years later in life (Adler RA, 2011) and are 
less likely to survive with a mortality rate as high as 37.5% after hip fracture (Bass et 
al., 2007; Jiang et al., 2005). Apart from bone fractures due to osteoporosis, bone 
parameters across different types of hip osteoarthritis and their relationship to 
osteoporotic fracture risk have also been widely studied (Castano-Betancourt et al, 
2013). 
Inflammatory cytokines, especially tumor necrosis factor a (TNF-a), have been 
shown to inhibit osteogenic differentiation of mesenchymal stem cells (MSCs) and 
bone formation in esfrogen deficiency-induced osteoporosis, but the mechanism 
responsible remains poorly understood. MicroRNAs (miRNAs) have been shown to 
regulate MSC differentiation (Yang et al., 2013). Recent study reported by Yang et 
al., 2013 has identified a novel mechanism whereby TNF-a, suppressing the 
fimctional axis of a key miRNA (miR-21) contributes to estrogen deficiency-induced 
osteoporosis. In the same study, they screened differentially expressed miRNAs in 
MSCs derived from estrogen deficiency-induced osteoporosis and found miR-21 was 
significantly downregulated. miR-21 was suppressed by TNF-a during the 
osteogenesis of MSCs. Furthermore, miR-21 was confirmed to promote the osteoblast 
differentiation of MSCs by repressing Spryl, which can negatively regulate the 
osteogenic differentiation of MSCs. Up regulating miR-21 partially rescued 
TNF-a-impaired osteogenesis of MSCs. Blocking TNF-a ameliorated the 
inflammatory enviroimient and significantiy enhanced bone formation with increased 
miR-21 expression and suppressed Spryl expression in ovariectomised (OVX) mice. 
Our results revealed a novel fimction for miR-21 and suggested that suppressed 
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miR-21 may contribute to impaired bone formation by elevated TNF-a in estrogen 
deficiency-induced osteoporosis (Yang et al., 2013). 
A number of studies have reported increased production of TNF by cultures of 
mononuclear cells derived from osteoporosis patients, an effect reversed by estrogen 
replacement (Shevde et al., 2000) and that ROS may play a role in bone loss in 
osteoporosis patients by generating a more oxidized bone microenvironment 
(Almeida and O'Brien, 2013). Based on these finding, we probed here the 
management and/or regulation of ROS and TNF-a activation in osteoporosis patient 
monocytes. The mechanisms of cellular activation as well as TNF-a and ROS 
enhancement would definitely help in better understanding the pathogenesis of 
osteoporosis. 
TNF-a is implicated in the pathophysiology of bone metabolism. The presence of 
elevated levels of TNF in the bone marrow of ovx animals and in the conditioned 
media of peripheral blood cells of postmenopausal women as well as osteoporosis 
patient is well documented (Pacific! R, 2010). Moreover, ROS are also involved in the 
etiopathology and progression of osteoporosis as reported earlier, and that, radicals 
generated in cells of osteoporosis patient stimulate TNF-a, causing accelerated bone 
loss. 
We used allicin from garlic and EGCG from green tea in the present study whose 
exact mechanism underlying their antioxidant activity still remains poorly understood. 
Allicin-induced enhancement of GPx activity has been reported (Perchellet, 1986; 
Bryk et al, 2002). To the best of our knowledge, we show for the first time that allicin 
exerts potent anti-inflammatory effects on osteoporosis patient mononuclear cells. 
Since higher doses of allicin (>100 \iM) and EGCG (23 |ig/ml) have proven 
toxic (Ankri et al, 1997; Hasan et al, 2006; Kawai et al 2005), thus prior to all 
investigations, cell viability and potential cytotoxicity were determined for the doses 
employed in this study using trypan blue and MTT assay where viability of-98-99% 
was observed with the lower doses selected in the present study (data not shown). 
Moreover, our laboratory has previously demonstrated that the doses employed in the 
present study for allicin or EGCG had no effect on human housekeeping genes 
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namely R18, thereby demonstrating that the effect of allicin or EGCG, was not 
mediated by cellular death, but rather by specific inhibition of expression and 
secretion of pro-inflammatory molecules (Hasan et al., 2006; Singh et al, 2002; 
Fatima et al, 2012). Hence, data has not been shown here. 
The real time RT-PCR results indicate an appreciable / high degree of down-
regulation in endogenous TNF-a mRNA expression by allicin and EGCG in 
osteoporosis patient monocytes. Similarly, both allicin and EGCG down-regulated the 
augmented OPG mRNA expressions in osteoporosis patient monocytes. Our results 
are in accordance to similar pattern observed by other workers with different 
antioxidants than ours (Nazrun et al., 2012). TNF-alpha production in monocytes is 
regulated at multiple intracellular levels, beginning with transcription (Raabe et al., 
1998).Augmented expression of TNF-a mRNA_and activation of a relevant 
transcription factor, NF-KB, have been reported in monocytic cells derived from 
osteoporosis patient. Consistent with earlier finding, we also report here the 
upregulation of Tl^F-a mRNA expression as well as activation of NF-KB in human 
monocytes derived from osteoporosis patients. 
The induction of TNF-a expression was observed to be mediated through activation 
of NF-KB, as evidenced by the suppression of TNF-a mRNA in the presence of SN50, 
an inhibitor of NI^ -^KB. On the contrary, the control SN50/M, an inactive analogue of 
SN50, failed to show any such effect. It has been well established that TNF-a induced 
nuclear translocation of NF-KB was inhibited by SN50 peptide as demonstrated in 
EMSA (Lin etal., 1995). 
In view of it, our data demonstrated that this effect involved inhibition of the NF-KB 
pathway induced by allicin as well as EGCG, probably by inhibiting the degradation 
of iKBa. The NFKB heterodimer is retained in the cytoplasm in an inactive form 
through association with one of the IKBS inhibitory proteins. As a consequence of 
stimulation by TNF-a, the kBa gets phosphorylated by a specific kinase complex 
(IKK) leading to its ubiquitination, and subsequent proteolysis by the 
28S proteosome (Lang et al., 2004; Li and Verma, 2002). The degradation of IKB 
releases active NF-KB, which translocates to the nucleus and regulates gene 
expression by binding to KB binding sites or by interacting with other transcriptional 
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factors (Brown et al, 1995). Since a number of genes involved in inflammatory 
responses are regulated by NF-KB pathway, thus a high magnitude downregulation of 
the NF-KB pathway by allicin and or EGCG would predictably reduce the elaboration 
of NF-KB-mediated TNF-a mRNA expression. In addition, both allicin and EGCG 
exerted a higher degree of neutralizing effects than NAC on TNF-a induced actions in 
osteoporosis patient monocytes. 
It's well established that glutathione directly reacts with ROS, and GPx catalyzes 
the removal of hydi-ogen peroxide (Mesiter and Anderson, 1983). Down-regulation or 
decrease in GPx activity indicates impairment of hydrogen peroxide-neutralizmg 
mechanisms (Rukmini et al., 2004). Here, we observed an appreciably suppressed 
GPx activity in osteoporosis patient monocytes that were imtreated with allicin or 
EGCG, thereby correlating with earlier reports that substantial amounts of ROS are 
being generated in bone cells of osteoporosis patient due to lowering of antioxidant 
defence in such cells. Enhancement of GPx activity in osteoporosis patient monocyte 
cultures after addition of NAC, a precursor of in vivo antioxidant glutathione, 
indicates reversal of impaired neutralizing mechanisms. Surprisingly, here slightly 
augmented GPx activity was observed when allicin or EGCG was co-cultured instead 
of NAC, indicating allicin and EGCG to be an effective natural antioxidant combating 
ROS, generated as a consequence of cellular activation in osteoporosis patient 
monocytes. Thus, our study shows amelioration in GPx activity by allicin and EGCG, 
which in turn, correlated inversely with the downregulation of TNF-a mRNA 
expression and ROS in monocytes of osteoporosis patients. 
In our study, peripheral blood mononuclear cells (PBMCs) were used directly for the 
generation of osteoclast precursors. The multinucleated osteoclast precursors were 
observed to appear on day 3 and the number increased after 5 days of culture, as 
revealed by Tantrate Resistant Acid Phosphatase (TRAP) staining. However, there 
was no appearajice of osteoclast precursors after 24 h (1 day) of culture (data not 
shown). The nujmber of multinucleated preosteoclasts, arising from PBMCs isolated 
from the blood of normal healthy individual (data not shown) and osteoporotic 
patients were counted by TRAP staining. Interestingly, we observed an individual 
variation in osteoclast generation from different donors. 
Page 149 
Discussion 
Our data exhibits that the multinucleated cells in monocyte cultures have numerous of 
the characteristics of osteoclasts. The data shows that cells in our cultures were large 
and multinucleated with ultrastructural features of osteoclasts, including a peripheral 
cytoplasmic clear zone devoid of subcellular organelles, and extensive cell surface 
folds and branched pleomorphic mitochondria. Such a finding is in agreement with 
earlier reporting (Ibbotson et al., 1984). These particular ultrastructural features are 
found in treshly isolated osteoclasts and in osteoclasts not lying adjacent to an 
endosteal bone surface (Ibbotson et al, 1984; Osdoby et al, 1982). Although 
numerous plasmalemmal folds and indentations were also regularly observed in our 
cultured cells, we did not identify the classical ruffled borders as reported for 
osteoclasts found adjacent to bone in Howship's lacunae in vivo (Ibbotson et al., 1984; 
Holtrop and king, 1997). 
The multinucleated cells in our cultures had other characteristics of osteoclasts. This 
was evident from the observation that they were responsive to treatment with the 
autocrine cytokine namely TNF-alpha that influence osteoclastic activity. TNF-alpha 
(2 ng/ml) increased the numbers of multinucleated cells in the cultures. This effect 
was inhibited by natural antioxidants like allicin and EGCG. Osteoclasts have been 
shown before to form by fusion (Jee and Nolan, 1963; Ibbotson et al, 1984), and the 
results of the current investigation suggest that this process is probably stimulated by 
TNF-alpha and inhibited by natural antioxidants like allicin and EGCG. Our data 
suggests that the mononuclear precursor cell of these multinucleated cells is immature 
marrow monocyte macrophage. The progenitor cells stained heavily with nonspecific 
esterase were phagocytic and appear similar to other monocytes-macrophages with 
Wright's-Giemsa staining (data not shown). 
Interestingly, we observed that co-culturing of PBMCs with EGCG (20 i^g/ml) or 
Allicin (500 ngy'ml) in osteoclastogenic medium for 3 and 5 days resulted in an 
appreciable amount of reduction in appearance of multinucleated osteoclast 
precursors, thereby reflecting the potential of EGCG and allicin to exert regulatory 
effect in osteoclast generation and differentiation. Nearly 20-25% suppression in 
appearance of multinucleated cells was observed in cultures receiving 15 and 
20 ^g/ml of EGCG relative to control cultures devoid of any EGCG. Interestingly, 
around 30-35% suppression in appearance of multinucleated cells was observed in 
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cultures receiving 250 and 500 ng/ml of allicin relative to control cultures devoid of 
any allicin. 
In addition to the above, our data revealed that allicin down regulated / suppressed the 
secretion of sRANKL by around 17.34%, 40.93%, 68.83% and 86.92% with 50, 100, 
250 and 500 ng/ml allicin respectively. The IC50 was computed out to be in between 
100-125 ng/ml. Similarly, analysis of the data revealed that EGCG down regulated / 
suppressed the secretion of sRANKL by around 14.82%, 31.24%, 47.04%, 59.96% 
and 71.08% with 2, 5, 10, 15 and 20 ^g EGCG respectively. The IC50 was computed 
out to be in between 7.5-10 ^g/ml of EGCG. Furthermore, our data shows that 
TNF-alpha up-regulated the levels of sRANKL in culture monocytes of osteoporosis 
patients. On the contrary, when TNF-a was co-cultured along with allicin or EGCG, 
then allicin inhibited the secretion of sRANKL by around 60% whereas EGCG 
inhibited the same by around 44%. Therefore, the present study provides for the first 
time evidences that Allicin from garlic as well as EGCG from green tea inhibits 
RANKL mediated signalling events that lead to osteoclast differentiation and fimction 
in monocyte cultuires. Incubation of osteoclast progenitor cells with allicin or EGCG 
inhibited TRAP activity and OPG expression in a dose dependent manner. 
These findings are novel and contribute to define a mechanism for the altered bone 
turnover in osteoporosis patients that, in turn, may protect patients from early bone 
loss or lead to increased bone mass. Bone mass is tightly regulated by osteoclastic and 
osteoblastic bone remodelling. The contribution of natural antioxidants like allicin 
from garlic as well as green tea polyphenol namely EGCG to bone remodelling in 
vivo is poorly understood. Our findings are suggestive that allicin and EGCG to 
inhibit osteoclastogenesis, likely by preventing the formation of pre-osteoclast cells 
capable of fiising into multinucleated osteoclasts. 
ROS including superoxide anion and hydrogen peroxide (H2O2) have been recognized 
as major intermediaries in the formation and activation of osteoclasts in vitro and in 
vivo (Wittrant et al., 2008; Suda et al., 1993; Garrett et al., 1990; Lee et al., 2005). 
Recent studies indicate that RANKL-mediated ROS production serves to regulate 
RANKL signalling pathways required for osteoclast differentiation (Koh et al., 2006; 
Ha et al., 2004; Wittrant et al., 2008). In RAW264.7 and BMM precursor cells. 
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RANKL increases ROS, whereas expression of catalase in BMM cells blocks 
RANKL-induced ROS production and inhibits the formation of TRACP (+) 
osteoclasts (Wittrant et al., 2008; Lee et al., 2005). These effects were reported to be 
correlated with the decreased formation of multinucleated osteoclast-like cells in the 
TRACP assays and likely contributed to the inability of these cells to differentiate in 
response to RANKJL. 
Therefore, in summary, our data regarding regulation of TNF-alpha, sRANKL, OPG, 
GPx activities, osteoclast formation and differentiation, etc by allicin from garlic as 
well as EGCG from green tea could provide a valuable tool in probing the control 
molecular mechanism of osteoporosis, and in turn, such natural antioxidants may 
serve as adjuncts in the management of osteoporosis. 
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In conclusion, it can be inferred from the present study that: 
1. There was appreciable degree of suppression in GPx activity in both sera as 
well as in monocyte cultures of osteoporosis patients. 
2. Intramonocyte GSH levels also exhibited significant dovm-regulation in 
osteoporosis patients. 
3. Both, allicin from garlic and EGCG from green tea dose-dependently 
amelioratedl/up-regulated the suppressed GPx activity as well as GSH levels in 
osteoporosis patients. 
4. Reactive oxygen species (ROS) mediated activation of monocyte of 
osteoporosis patients resulted in the induction of augmented basal levels of 
TNF-alphaand IL-lp. 
5. Both, allicin from garlic and EGCG from green tea efficiently caused 
down-regulation in TNF-alpha and IL-lb in both sera as well as in monocyte 
cultures of osteoporosis patients. 
6. There was appreciably high levels expression of TNF-alpha and OPG mRNA 
in monocytes of osteoporosis patients. 
7. 20 |Lig/ml of EGCG and 500 ng/ml of allicin exhibited no toxic effect on the 
viability of human house keeping gene Rl 8. 
8. Both, EGCG and allicin dose-dependently down-regulated the expression of 
TNF-alpha and OPG mRNA in monocytes of osteoporosis patients. 
9. Both, EGCG and allicin that were separately co-cultured with PBMCs in 
osteoclastogenic medium for 3 and 5 days resulted in an appreciable amount 
of reduction in appearance of multinucleated osteoclast precursors. Hence, this 
reflects the potential of EGCG and allicin to exert regulatory effect in 
osteoclast generation and differentiation. 
10. In compjirison to healthy confrols, osteoporosis patient's cultures exhibited 
around 9-fold augmented levels of sRANKL. 
11. Both allicin and EGCG dose-dependently decreased sRANKL secretion 
osteoporosis patients. 
12. Both, EGCG and allicin exhibited potential antioxidant as well as anti-bone 
resorptive properties as suggested from results observed from down-regulation 
of bone markers like TNF, IL-ip, sRANKL and OPG. 
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Thus, in summary, based on the results, it is hoped that the present study 
would be of immense help in the better understanding of osteoporosis 
management by employing natural antioxidants. 
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